Alliance A 222001  
1 
Version Date  09/14/22  Update #02  ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY  
ALLIANCE A 222001  
A RANDOMIZED , DOUBLE -BLIND , PLACEBO -CONTROLLED PHASE II STUDY OF OXYBUTYNIN VERSUS 
PLACEBO FOR THE TREATMENT OF HOT FLASHES IN MEN RECEIVING ANDROGEN DEPRIVATION 
THERAPY  
A limited access study  
Supplied agent: oxybutynin (Alliance IND : 152980 , NSC  759108 ) 
ClinicalTrials.gov Identifier: N CT04600336  
 
Study Chair  
  
  
 
 
 
 
 
 
Community Oncology Co -chair  Study Co-chair  Study Co-chair  
   
    
   
   
 
Symptom Intervention Committee 
and Study Co -chair Health Disparities Co -chairs 
   
     
   
   
 
Primary Statistician  Secondary Statistician  
  
  
  
 
Data Manager  Protocol Coordinator  
  
   
  
 
Limited Access Institutions: See page 2 -3 
 
Participating Organizations :  
Alliance/Alliance for Clinical Trials in Oncology (lead), ECOG -ACRIN/ECOG -ACRIN Cancer Research Gro up, 
NRG/NRG Oncology, SWOG/SWOG    

Alliance A 222001  
2 
Version Date  09/14/22  Update #[ADDRESS_903770] Cancer Specialists -Scottsdale, AZ146  
Arizona Cancer Care -Surprise, AZ149   
Arizona Center for Cancer Care -Peoria, AZ127  
Ascension All Saints Hospi[INVESTIGATOR_307], WI061   
Ascension Calumet Hospi[INVESTIGATOR_307], WI204   
Ascension Colombia Saint Mary’s Hosp -Milwaukee, 
WI161   
Ascension Colombia Saint Mary’s Hosp -Ozaukee, 
WI140   
Ascens ion Med Group SE Wisc. -Mayfair Road, 
WI169   
Springfield Clinic, IL194  
Ascension Mercy Hospi[INVESTIGATOR_307], WI038   
Ascension Saint Elizabeth Hospi[INVESTIGATOR_307], WI039   
Ascension Saint Francis -Reiman Cancer Center, 
WI137   
Ascension Saint Joseph Hospi[INVESTIGATOR_307], MI364  
Ascension Saint Ma ry’s Hospi[INVESTIGATOR_307], MI142   
Ascension SE Wisc. Hospi[INVESTIGATOR_307] -Elmbrook Campus, 
WI145   
Ascension SE Wisc. Hospi[INVESTIGATOR_307] -St Joseph Campus, 
WI043   
Aspi[INVESTIGATOR_669059] -Wisconsin Rapi[INVESTIGATOR_805], WI093  
Aspi[INVESTIGATOR_669060], WI146   
Aspi[INVESTIGATOR_669061], WI028   
AtlantiCar e Cancer Care Institute, NJ237  AtlantiCare Health Park -Cape May Court House, 
NJ287   
Baptist MD Anderson Cancer Center, FL003  
Cancer Care Specialists of IL -Decatur, IL185   
Cancer Center at Saint Joseph’s, AZ151   
Carle Cancer Center, IL168   
Carle on Vermilli on, IL405   
Carle Physician Group -Effingham, IL406   
Carle Physician Group -Mattoon/Charleston, IL393   
Crossroads Cancer Center, IL208   
Decatur Memorial Hospi[INVESTIGATOR_307], IL094   
Delbert Day Cancer Institute at PCRMC, MO052  
Fairview Clinics and Surgery Center -Maple Grove, 
MN113   
Fairview Lakes Medical Center, MN132  
Fairview Ridges Hospi[INVESTIGATOR_307], MN070   
Fairview Southdale Hospi[INVESTIGATOR_307], MN031  
Fremont -Rideout Cancer Center, CA564  
Gene Upshaw Memorial Tahoe Forest Therapy Ctr, 
CA690  
Genesee Cancer and Blood Disease Treatment Ctr, 
MI347  
Genesee Hematology Oncology, MI348  
Genesys Hurley Cancer Center, MI149  
Grand Valley Oncology, CO138  
Hawaii Cancer Care Inc, HI022  
Hawaii Cancer Care -Westridge, HI049  
Heartland Oncology and Hematology, IA147  
Hennepin County Medical Cent er, MN013  
Iowa Methodist Medical Center, IA004  
Alliance A 222001  
3 
Version Date  09/14/22  Update #[ADDRESS_903771] Hospi[INVESTIGATOR_307], NE007   
New Ulm Medical Center, MN121  
North Memorial Medical Health Center, MN054  
NYP/Weill Cornell Medical Center, NY018   
Ohio State University Com prehensive Cancer Center, 
OH007   
Oncology Hematology Assoc of Saginaw, MI364  
Park Nicollet Clinic -St Louis Park, MN014  ProHealth D N Greenwald Center, WI143  
ProHealth Oconomowoc Memorial Hospi[INVESTIGATOR_307], WI087  
Regions Hospi[INVESTIGATOR_307], MN001  
Rice Memorial Hospi[INVESTIGATOR_307], MN028  
Ridgeview Medical Center, MN059  
Saint Francis Regional Medical Center, MN064  
Saint John’s Hospi[INVESTIGATOR_307] -Healtheast, MN041  
Sanford Broadway Medical Center, ND003  
Sanford Cancer Center Oncology Clinic, SD004  
Sanford Roger Maris Cancer Center, ND005  
Sanford USD Medical Center, SD003  
Southeastern Medical Oncology Center -Clinton, 
NC254  
Southeastern Medical Oncology Center -Goldsboro, 
NC065  
Southeastern Medical Oncology Center -Jacksonville, 
NC231  
Southern Illinois School of Medicine, IL096  
Sovah Health Ma rtinsville, VA043  
Sparta Community Hospi[INVESTIGATOR_307], IL413  
Springfield Memorial Hospi[INVESTIGATOR_307], IL097  
United Hospi[INVESTIGATOR_307], MN002  
Unity Hospi[INVESTIGATOR_307], MN018  
University of Arizona Cancer Center -North Campus, 
AZ110  
University of Mississippi [INVESTIGATOR_60584], MS005  
University of Misso uri-Ellis Fischel, MO036  
UW Cancer Center at ProHealth Care, WI207  
Westfields Hosp/Cancer Center of Western WI, 
WI196   
Zablocki Veterans Administration Medical Cetner, 
WI004  
 
Alliance A 222001  
4 
Version Date  09/14/22  Update #02  Study Resources:  
Expedited Adverse Event Reporting  
 Medidata Rave  iMedidata portal  
 
OPEN (Oncology Patient Enrollment Network)  
 Biospecimen Management System  
 
 
Protocol Contacts:  
A222001  Nursing Contact s 
 
 
 
 
 A222001  Pharmacy Contact  
 
  
   
  
 
[CONTACT_669079] -related questions may be directed as follows:  
Questions  Contact (via email)  
Questions regarding patient eligibility, treatment, 
and dose modification:  Study Chair, Nursing Contact, Protocol 
Coordinator, and (where applicable) Data 
Manager  
Questions related to data submission, RAVE or 
patient follow -up: Data Manager  
Questions regarding the protocol document and 
model informed consent:  Protocol Coordinator  
Questions related to IRB review  Alliance Regulatory Inbox  
 
Questions regarding CTEP -AERS reporting:  Alliance Pharmacovigilance Inbox 
 
Questions regarding drug supply  McKesson Clinical Research Services   
Questions regarding drug administration  Pharmacy Contact  
 
 
  

[CONTACT_669080] A 222001  
5 
Version Date  09/14/22  Update #02  CANCER TRIALS SUPPORT UNIT (CTSU) ADDRESS AND CONTACT [CONTACT_669081]:  For patient enrollments:  For data submission:  
Regulatory documentation must 
be submitted to the Cancer 
Trials Support Unit (CTSU) via 
the Regulatory Submission 
Portal.  
 (Sign in at 
 and select 
the Regulatory > Regulatory 
Submission.)  
 
Institutions with patients 
waiting that are unable to use 
the Portal should alert the 
CTSU Regulatory Office 
immediately by [CONTACT_61529]: 
 
to 
receive further inst ruction and 
support.  
 
Contact [CONTACT_311326] 1  
for regulatory assistance.  Refer to the patient enrollment 
section of the protocol for 
instructions on using the 
Oncology Patient Enrollment 
Network (OPEN). OPEN is 
access ed at 
 
 
Contact [CONTACT_669082]  : 
 
 
 
 Data collection for this study 
will be done exclusively through 
Medidata Rave. Refer to the data 
submission section of the 
protocol for further instructions.  
 
 
The most current version of the study protocol and all supporting documents  must be downloaded 
from the protocol -specific page located on the CTSU members’ website Access 
to the CTSU members’ website is managed through the Cancer Therapy and Evaluation Program - 
Identity and Access Management (CTEP -IAM) registration system and requires log in with a CTEP -
IAM username [CONTACT_2383].  
 
Permission to view and download t his protocol and its supporting documents is restricted and is based 
on person and site roster assignment housed in the CTSU Regulatory Support System (RSS).    
 
Supplies can be ordered by [CONTACT_669083] (available on 
the protocol -specific page on the CTSU website) and submitting it as instructed on the form.  
 
For clinical questions (i.e. patient eligibility or treatment -related)  see the Protocol Contacts, Page 4. 
 
For non -clinical questions (i.e. unrelated to pati ent eligibility, treatment, or clinical data 
submission)  Contact [CONTACT_379502]:   
CTSU General Information Line – All calls and 
correspondence will be triaged to the appropriate CTSU representative.  
 
 

Alliance A 222001  
6 
Version Date  09/14/22  Update #02  A RANDOMIZED , DOUBLE -BLIND , PLACEBO -CONTROLLED PHASE II STUDY OF OXYBUTYNIN VERSUS 
PLACEBO FOR THE TREATMENT OF HOT FLASHES IN MEN RECEIVING ANDROGEN DEPRIVATION 
THERAPY  
Eligibility Criteria (see  Section 3.0 ) Required Initial Laboratory Values  
• Men who are currently receiving a ndrogen 
deprivation therapy (ADT) for the treatment of 
prostate cancer. (See §3.2.1 ) None  
• Patients must be on a stable dose of all hormone -directed therapi[INVESTIGATOR_129528] 28 days prior to 
registration . Patients receiving radiati on therapy are eligible. (See §3.2.2 ) 
• Eligible patient must have bothersome hot flashes for ≥ 14 days prior to registration . (See §3.2.3 ) 
• No current or future planned use of any of the  agents listed in Section  3.2.4 during the study period.  
(See §3.2.4)  
• No current or prior use of oxybutynin  as a treatment for  hot flashes . (See §3.2.5 )  
• Patients with a history of any of the contraindications to oxybutynin  listed in Section  3.2.6 are not 
eligible. ( See §3.2.6 ) 
• IPSS score < 20  (See §3.2.8 ) 
• Life expectancy of greater than 6 months. (See §3.2.9 ) 
• Age ≥ 18 years . (See §3.2. 10) 
• ECOG Performance Status 0 , 1 or 2. (See  §3.2. 11) 
• Participants must be able to speak and read English. (See §3.2.1 2) 
 
Schema  
  Initial Blinded Phase     Optional Unblinded Phase  
R  Oxybutynin 2.5 mL** p.o. BID for 42 days***   R   
A   E   
N    R  Oxybutynin 2.5 mL*** 
p.o. BID for 42 days  D  Placebo  2.5 mL** p.o. BID for 42 days***   E  
O   G  
M    I   
I  
Oxybutynin  5.0 mL**  p.o. BID for 42 days***   S   
Z   T   
E*    E  Oxybutynin  5.0 mL***  
p.o. BID for 42 days    Placebo 5.0 mL p.o.**  BID for 42 days *** 
  R  
* Days 1 -7 of study will involve collection of BSD (Baseline Symptom Documentation). Study t reatment 
is to be administered from Days 8-49.  
** The concentratio n of oxybutynin is 1 mg per 1 mL , so that placebos and active treatments will maintain 
blinding.  
*** Following 6 we eks of study treatment, the patient  will be given the option of being unblinded  (Section 
8.3.2 ), and if he was on  placebo, will be allowed to cross -over, be re-registered  (See Section 4.7 ), 
receive either 2.5 or 5.0 mL of oxybutynin, equivalent to the amount of the placebo the patient had 
received prior to unblinding, for 6 weeks. .  
Please refer to the full protocol text for a complete description of the eligibility criteria and 
treatment plan.  
If the Group credited for enrollment is a non -Alliance Group, then other requirements from the credited 
Group may apply.   
Alliance A 222001  
7 
Version Date  09/14/22  Update #02  Table of Contents  
Section  Page  
1.0 BACKGROUND AND RATIONALE  ................................ ................................ ..........................  9 
1.1 Treatment of Hot Flash es in Men  ................................ ................................ ................................ . 9 
1.2 Oxybutynin for Hot Flashes  ................................ ................................ ................................ ..........  9 
1.3 Study Design  ................................ ................................ ................................ ...............................  10 
2.0 OBJECTIVES  ................................ ................................ ................................ ...............................  11 
2.1 Primary objective  ................................ ................................ ................................ ........................  11 
2.2 Secondary objectives  ................................ ................................ ................................ ..................  11 
3.0 PATIENT SELECTION ................................ ................................ ................................ ...............  12 
3.1 On-Study Guidelines  ................................ ................................ ................................ ...................  12 
3.2 Eligibility Criteria  ................................ ................................ ................................ .......................  12 
4.0 PATIENT REGISTRATION  ................................ ................................ ................................ ....... 14 
4.1 Investigator and Research Associate Registration with CTEP  ................................ ...................  14 
4.2 CTSU Site Registration Procedure s ................................ ................................ ............................  15 
4.3 Patient Registration Requirements  ................................ ................................ ..............................  17 
4.4 Patient Enrollment (registration/randomization procedures (Step 1))  ................................ ........  17 
4.5 Stratification Factors and Treatment Assignments  ................................ ................................ ..... 18 
4.6 Procedures for Double -Blinding the Treatment Assignment  ................................ ......................  19 
4.7 Cross -Over Re -registration (step 2) Procedures  ................................ ................................ .........  19 
5.0 STUDY CALENDAR  ................................ ................................ ................................ ...................  20 
6.0 DATA SUBMISSION  ................................ ................................ ................................ ...................  21 
6.1 Data  Collection and Submission  ................................ ................................ ................................ . 21 
6.2 Submission of Patient Completed Measures  ................................ ................................ ...............  22 
7.0 TREATMENT PLAN/INTERVENTION  ................................ ................................ ...................  23 
7.1 Baseline Symptom Documentation  ................................ ................................ .............................  23 
7.2 Oxybutynin/Placebo  ................................ ................................ ................................ ....................  23 
7.3 Patient Unblinding and optional crossover  ................................ ................................ .................  23 
8.0 DOSE AND TREATMENT MODIFICATIONS, UNBLINDING  ................................ ...........  24 
8.1 Ancillary Therapy, Concomitant Medications, and Supportive Care  ................................ .........  24 
8.2 Dose Modifications  ................................ ................................ ................................ .....................  24 
8.3 Unblinding Procedures  ................................ ................................ ................................ ................  25 
9.0 ADVERSE EVENTS  ................................ ................................ ................................ ....................  26 
9.1 Routine Adverse Event Reporting  ................................ ................................ ..............................  26 
9.2 CTCAE Routine Reporting Requirements  ................................ ................................ ..................  26 
9.3 Expedited Adverse Event Reporting (CTEP -AERS)  ................................ ................................ .. 27 
10.0  DRUG INFORMATION  ................................ ................................ ................................ ..............  29 
10.1  Oxybutynin Chloride Oral Syrup (Ditropan)  ................................ ................................ ..............  29 
10.2  Placebo Oral Solution  ................................ ................................ ................................ .................  33 
11.0  MEASURES  ................................ ................................ ................................ ................................ .. 34 
11.1  Baseline Symptom Determination (Appendix II)  ................................ ................................ ....... 34 
11.2  International Prostate Symptom Score (IPSS) (Appendix  III) ................................ ....................  34 
11.3  Hot Flash Diary (Appendix IV)  ................................ ................................ ................................ .. 34 
11.4  Symptom Experience Questionnaire (Appendix V)  ................................ ................................ ... 34 
11.5  Hot Flash Related Daily Interference Scale (HRFDIS) (Appendix VI)  ................................ ...... 35 
Alliance A 222001  
8 
Version Date  09/14/22  Update #[ADDRESS_903772] (Appendix VII)  ................................ ................................ ..................  35 
12.0  END OF TREATMENT/INTERVENTION  ................................ ................................ ..............  35 
12.1  Duration of Protocol Treatment  ................................ ................................ ................................ .. 35 
12.2  Criteria for Discontinuation of Protocol Treatment/Intervention  ................................ ...............  35 
12.3  Follow -up ................................ ................................ ................................ ................................ .... 36 
12.4  Extraordinary Medical Circumstances  ................................ ................................ ........................  36 
12.5  Managing ineligible patients and registered patients who never receive protocol intervention  . 36 
13.0  STATISTICAL CONSIDERATIONS  ................................ ................................ ........................  37 
13.1  Overview  ................................ ................................ ................................ ................................ ..... 37 
13.2  Study Des ign ................................ ................................ ................................ ...............................  37 
13.3  Study Endpoints  ................................ ................................ ................................ ..........................  37 
13.4  Analysis Plan  ................................ ................................ ................................ ..............................  37 
13.5  Sample Size and Power  ................................ ................................ ................................ ...............  39 
13.6  Accrual Time and Study Duration  ................................ ................................ ..............................  40 
13.7  Data and Safety Monitoring  ................................ ................................ ................................ ........  40 
13.8  Minority Accrual  ................................ ................................ ................................ .........................  40 
13.9  Inclusion of Minorities  ................................ ................................ ................................ ................  41 
14.0  GENERAL REGULATORY CONSIDERATIONS AND CREDENTIALING  .....................  42 
14.1 Limited Access Requirements  ................................ ................................ ................................ ........  42 
15.0  MONITORING PLAN  ................................ ................................ ................................ .................  42 
16.0  REFERENCES  ................................ ................................ ................................ ..............................  43 
APPENDIX I HOT FLASH DEFINITIONS FOR THE MALE PATIENT  ................................ ....... 46 
APPENDIX II BASELINE SYMPTOM DOCUMENTATION  ................................ ...........................  47 
APPENDIX III INTERNATIONAL PROSTATE SYMPTOM SCORE (IPSS)  ................................  48 
APPENDIX IV HOT FLASH DIARY (SAMPLE INCLUDED ON THE NEXT PAGE)  .................  50 
APPENDIX V SYMPTOM EXPERIENCE QUESTI ONNAIRE  ................................ ........................  52 
APPENDIX VI HOT FLASH RELATED DAILY INTERFERENCE SCALE (HFRDIS) ...............  56 
APPENDIX VII NURSE/CRP PHONE CONTACT [CONTACT_110616]  ................................ ...............................  57 
APPENDIX VIII: PATIENT MEDICATION DIARY – OXYBUTYNIN/PLACEBO  ......................  [ADDRESS_903773]  ................................ ........................  62 
APPENDIX XI PATIENT THANK YOU LETTERS  ................................ ................................ ...........  63 
 
 
  
Alliance A 222001  
9 
Version Date  09/14/22  Update #02  1.0 BACKGROUND  AND RATIONALE  
Therapi[INVESTIGATOR_669062], and also in certain salivary gland tumors. [1, 2]  Additionally, medications to block 
estrogen signaling are also commonly employed in men with estrogen and/or progesterone receptor 
positive breast cancer. [3] Although these therapi[INVESTIGATOR_669063], a rapid 
change in the circulating hormone levels can commonly cause patients to expe rience symptomatic 
hot flashes. Approximately 60 -80% of prostate cancer patients being treated with either surgical (i.e. 
orchiectomy) or medical androgen deprivation therapy (ADT) will experience hot flashes. [4, 5]  Hot 
flashes have been associated with negative impacts on patients’ reported quality of life, fatigue, and 
sleep disturbance. [6-11]  Additionally , patients with bothersome hot flashes may be less likely to 
complete the recommended course of ADT, which can negatively influence cancer prognosis. Given 
the prevalence of this symptom and the significance of associated to xicity, further study of potentially 
effective interventions is warranted.  
1.[ADDRESS_903774] randomized trial evidence 
demonstrating a significant reduction in hot flashes, with acceptable toxicity profiles. [12, 13]  
Both of these trials demonstrated that greater than 70% of patients receiving the study agents 
reported significant reductions in hot flashes. However, some oncologists are hesitant to 
prescribe these agents due to overexpression of progesterone receptors in a sub set of patients 
with prostate cancer, and the uncertain clinical effects of these medication on oncologic 
outcomes. [14-16] Megestrol has also been associated with a decrease  in prostate -specific 
antigen (PSA) after withdrawal suggesting  some potential therapeutic effect by [CONTACT_33641] .[17] 
Gabapentin, a gamma -aminobutyric acid analog, has also been shown to be effective at reducing 
hot flash frequency compared to placebo in men receiving ADT. [18] In that study, a dose -
dependent response to gabapentin was noted, with only patients receiving the highest dose (900 
mg/day) demonstrating a statistically significant moderate improvement in hot flash scores and 
frequencies, compared to placebo. However, there was only a 20% reduction and that only 
appeared after 3 weeks. A rand omized trial assessing the efficacy of both venlafaxine, a 
serotonin -norepi[INVESTIGATOR_26331] (SNRI), and soy protein revealed that n either agent 
was effective at reducing hot flashes in men with prostate cancer. [19] This result is notable 
because venlafaxine has been shown, in multiple randomized studies, to improve hot flashes in 
women [20, 21] , thus demonstrating the importance of investigating gender -specific responses 
to interventions for managing hot flashes. While there are evidence -based options for treating 
male hot flashes, further study is warranted to identify additional interventions that provide both 
providers and patients with more effective means of hot flash management, with tolerable side 
effects.  
1.2 Oxybutynin for Hot Flashes  
Oxybutynin is an anti -cholinergic agent which is available in both oral and transdermal 
formulations. Curr ently, oxybutynin is approved by [CONTACT_2165] (FDA) 
for use in managing overactive bladder symptoms. Additionally there are randomized  trial data 
supporting off label use for the management of hyperhidrosis, with studies showing that th is 
effect is equal across both genders. [22-24] Oxybutynin has a very good safety profile, with the 
most common reported adverse effects being xerostomia, drowsiness, dizziness, mild cognitive 
effects, and urinary retention, w hich are typi[INVESTIGATOR_669064], if not tolerable. [25] 
In 2007, a manuscript reported retrospective data that supported the efficacy of oxybutynin for 
managing refractory hot flash symptoms in 52 cancer patien ts, including four men with ADT -
Alliance A 222001  
10 
Version Date  09/14/22  Update #02  induced hot flashes. [26] The promising results of this study, which suggested a 70% response 
rate to oxybutynin wit h acceptable toxicity, led to the development of Phase III, double -blind, 
randomized trials comparing oxybutynin to placebo in women with hot flashes. [27, 28]  One 
such trial demonstrated that moderate doses of oxybutynin substantially decreased hot flashes 
with mild to moderate toxicity. [27] More recently, our group completed another study which 
compared oxybutynin at doses of 2.[ADDRESS_903775] 
Cancer Symposium, and showed that hot flash scores were significantly reduced from baseline 
in both the 2.5 mg ( -10.6, SD 7.7) and 5.0 mg ( -16.9, SD 15.6) treatment arms compared to 
placebo ( -5.7, SD 10.2). Additionally, hot flash frequency was significantly improved for 
patients receiving both dose levels of oxybutynin (2.5 mg=60% reduction, 5.0 mg=77% 
reduction) over t hose treated with placebo (27% reduction). Reported treatment -related adverse 
effects for participants were typi[INVESTIGATOR_669065] . [28] 
Additionally, a recent letter to t he editor in the New England Journal of Medicine highlighted a 
case study of a man with hot flashes related to ADT which were refractory to high doses of 
gabapentin and venlafaxine, who then experienced a dramatic improvement after starting 
oxybutynin 2.5 mg twice daily. [29]  Furthermore, members of our study team have an ecdotally 
noted positive effects on hot flash symptoms when prescribing oxybutynin to manage urinary 
symptoms in men with prostate cancer. These observations, coupled with the positive effect of 
oxybutynin on hot flashes in women, support the conduct of a double -blind, placebo -controlled 
trial of oxybutynin for the management of hot flashes in men receiving ADT  with a primary 
endpoint assessing the change in hot flash scores from baseline .  
1.3 Study Design  
1.3.1 Baseline period:  
We will utilize a one week period to obtain data regarding baseline hot flashes.  
1.3.2  Hot flash measurement  
Patient reported outcome (PRO) measurements will be used as per the methodology that 
we described 18 years ago, [30] and that has also been used in trials conducted by [CONTACT_543215].  The primary endpoint of this study will assess the effects of the study 
interventions on patient reported hot flash scores. The calculation of this metric is defined 
in Section 2.1.1.  Definitions of hot flash severity in men will be provided, based on data 
we collected from male patients who participated in a previous hot flash trial, and published 
25 years ago. [31] Previous studies for hot flashes in men have utilized the same outcome 
measures to assess the study drug’s efficacy  and the hot flash score represents an ideal tool 
for quanti tating multiple aspects of hot flash symptomatology .[12, 18, 30 -32] We plan to 
use the Hot Flash Related Daily Interference Scale (HFRDIS), a tool developed by [INVESTIGATOR_124]. 
Janet Carpenter. [33]  We recently assessed face validity by [CONTACT_7939] [ADDRESS_903776] used the HFRDIS in men receiving androgen deprivation 
therapy .[34-36] These studies provide additional data supporting the reliability and validity 
of the 10 -item instrument in this population. For example, Gonzalez, et al., (2015) pr ovided 
evidence of construct validity in this population by [CONTACT_669084] A 222001  
11 
Version Date  09/14/22  Update #02  prostatectomy.  [34] Beer, et al. (2010) demonstrated decreasing scores on both the HFD 
and HFRDIS following acupuncture in men undergoing androgen deprivat ion therapy, 
supporting concurrent validity of the HFRDIS [34]. 
1.3.[ADDRESS_903777] to the effects of oxybutynin on neuro -cognition relativ e to 
placebo. [37-40] Questions relating to patient -reported cognition will be asked via the 
Symptom Experience Questionnaire (Appendix V) at baseline and weekly during the 6 -
week treatment period to help ascertain the effects of oxybut ynin relative to placebo. These 
data will ultimately provide insight regarding the potential for cognitive toxicity with 
oxybutynin, which can be useful when considering the therapeutic index of this medication 
for treating hot flashes.  
2.0 OBJECTIVES  
2.1 Primary objective  
2.1.1  To assess the effects of two doses of oxybutynin on hot flash scores (determined by 
[CONTACT_669085] [grade 0: none, 
1: mild, 2: moderate, 3: severe, and 4: very severe] and summing the values over a 24 -
hour period) relative to placebo.  
2.2 Secondary objectives  
2.2.1  To assess study accrual rates and compliance with the therapy.  
2.2.2  To characterize the safety and adverse e vent profile of two doses of oxybutynin in the 
study population.  
2.2.3  To evaluate the consistency of the results across the various methods used to evaluate the 
efficacy of oxybutynin (i.e., hot flash scores versus hot flash frequencies, mean 
differences versus  50% or greater reduction since baseline, single day versus full week to 
define patients’ baseline hot flash scores).  
2.2.4  To compare patient -reported quality of life and hot flash interference, as measured by [CONTACT_669086], across arms.  
2.2.5  To compare other changes in patient symptoms, as measured by [CONTACT_669087], across arms.  
  
Alliance A 222001  
12 
Version Date  09/14/22  Update #02  3.0 PATIENT  SELECTION  
For questions regarding eligibility criteria, see the Study Resources page. Please note that the Study 
Chair cannot grant waivers to eligibility requirements.  
3.1 On-Study Guidelines  
This clinical trial can fulfill its objectives only if patients appropriate for this trial are enrolled. 
All relevant medical and other considerations should be taken into account when deciding 
whether this protocol is appropriate for a  particular patient. Physicians should consider the risks 
and benefits of any therapy, and therefore only enroll patients for whom this treatment is 
appropriate.  
Physicians should consider whether any of the following may render the patient inappropriate 
for this protocol:  
• Psychiatric illness which would prevent the patient from giving informed consent.  
• Medical condition such as uncontrolled infection (including HIV), uncontrolled 
diabetes mellitus or cardiac disease which, in the opi[INVESTIGATOR_401107] p hysician, 
would make this protocol unreasonably hazardous for the patient.  
3.2 Eligibility Criteria  
Use the spaces provided to confirm a patient’s eligibility by [CONTACT_539034]. 
It is not required to complete or submit the following p age(s).  
When calculating days of tests and measurements, the day a test or measurement is done is 
considered Day 0. Therefore, if a test were done on a Monday, the Monday one week later would 
be considered Day 7.  
___ 3.2.1 Men who are currently receiving a ndrogen deprivation therapy (A DT) for the 
treatment of prostate cancer. ADT is defined by a history of orchiectomy, or ongoing 
usage of gonadotropin -releasing hormone agonists or antagonists . Men rece iving 
abiraterone,  but not  enzalutamide, apalutamide , and darolutamide are eligible , as the latter  
three are metabolized by [CONTACT_097]3A4 and may affect oxybutynin serum concentrations . 
___ 3.2.[ADDRESS_903778] b othersome hot flashes for ≥ 14 days  prior to 
registrati on, defined by [CONTACT_669088] ≥  28 times per week and of sufficient severity 
to cause the patient to seek therapeutic intervention.  
___ 3.2.4 No current use or future planned use of any of the following agents during the 
study period : drugs that are not FDA approved for use in humans, drugs with 
category X interactions with oxybutynin [e.g. other anti -cholinergic agents, 
eluoxadloline, and potassium chloride], androgens, estrogens, progesterone analogs, 
gabapentin,  cholinergic  agonists, cholinesterase inhibitors, or 
complementary/alternative medicine taken for the purpose of managing hot flashes . 
No current or future planned use of stro ng CYP3A4 inhibitors (e.g. a ntips ychotic 
agents or macrolide antibiotics)  during the study . 
Prior use of these agents is permitted as long as they are discontinued before  registration.  
Alliance A 222001  
13 
Version Date  09/14/22  Update #02  ____  3.2.5 No current or prior use of oxybutynin  for the treatment of hot flashes .  Prior 
use of oxybutynin for other purposes (e.g. bladder symptoms) is allowed, as long as 
the patient has not taken any oxybutynin for 30 days prior to registration.  
___ 3.2.6  Comorbid conditions  
Patients with a history of any of the following contraindications to oxyb utynin are not 
eligible:  gastroparesis or gastrointestinal obstructive disorders;  severe constipation  defined 
as 2 or fewer bowel movements per week; significant gastric reflux symptoms not 
controlled by [CONTACT_12617]; ulcerative colitis; narrow -angle glaucom a; hypersensitivity to 
oxybutynin or any other components of the product; current uncontrolled hyperthyroidism; 
uncontrolled coronary artery disease or a history of myocardial infarction within the prior 
12 months; NYHA Class II -IV congestive heart failure ; symptomatic cardiac arrhythmias; 
current uncontrolled hypertension  (average systolic >140 mm Hg and diastolic >90 mm 
Hg); myasthenia gravis;  Parkinson’s disease;  or dementia.  
___ 3.2.7 Patients with u rinary retention requiring indwelling or intermittent self-
catheterization within the prior 6 months are not eligibl e. 
___ 3.2.8 IPSS  (Appendix III) score  < [ADDRESS_903779] void residual 
confirmation of less than 300 cc residual in the bladder  (that is that the patient is 
eligible with a higher IPSS score if a subsequent PVR test looks good) .    
____  3.2.9 Life Expectancy of greater than 6 months . 
___ 3.2.10 Age ≥ 18 years  
___ 3.2.11 ECOG Performance Status - 0, 1, or 2  
___ 3.2.1 2 Language: In order to complete the mandatory patient -completed measure s, 
participants mus t be able to speak and/or read  English.  
___ 3.2.13 Required Initial Laboratory Values: None  
  
Alliance A 222001  
14 
Version Date  09/14/22  Update #02  4.0 PATIENT  REGISTRATION  
4.1 Investigator and Research Associate Registration with CTEP  
Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) policy 
require all individuals contributing to NCI -sponsored trials to register and renew their 
registration annually. To register, all individuals mu st obtain a Cancer Therapy Evaluation 
Program (CTEP) Identity and Access Management (IAM) account at 
 In addition, persons wi th a registration type of Investigator 
(IVR), Non -Physician Investigator (NPI[INVESTIGATOR_6731]), or Associate Plus (AP) must complete their annual 
registration using CTEP’s web -based Registration and Credential Repository (RCR) at 
    
RCR utilizes five person registration types.  
• IVR — MD, DO, or international equivalent;  
• NPI[INVESTIGATOR_6731] — advanced practice providers (e.g., NP or PA) or graduate level researchers 
(e.g., PhD);  
• AP — clinical site staff ( e.g., RN or CRA) with data entry access to CTSU applications 
such as the Roster Update Management System [RUMS], OPEN, Rave, acting as a 
primary site contact, or with consenting privileges;  
• Associate (A) — other clinical site staff involved in the conduct of NCI -sponsored trials; 
and 
• Associate Basic (AB) — individuals (e.g., pharmaceutical company employees) with 
limited access to NCI -supported systems.  
RCR requires the following registration documents:  
Documentation Required  IVR NPI[INVESTIGATOR_6732] A AB 
FDA Form 1572  ✔ ✔    
Financial Disclosure Form  ✔ ✔ ✔   
NCI Biosketch (education, training, employment, 
license, and certification)  ✔ ✔ ✔   
GCP training  ✔ ✔ ✔   
Agent Shipment Form (if applicable)  ✔     
CV (optional)  ✔ ✔ ✔   
 
An active CTEP -IAM user account and appropriate RCR registration is required to access all 
CTEP and Cancer Trials Support Unit (CTSU) websites and applications. In addition, IVRs and 
NPI[INVESTIGATOR_278537] (IRBs) covering 
their practice sites on the FDA Form 1572 in RCR to allow the following:  
• Addition to a site roster;  
• Assign the treating, credit, consenting, or drug shipment (IVR only) tasks in OPEN;  
• Act as the site -protocol Principal Investigator (PI) on the IRB approval; an d 
• Assign the Clinical Investigator (CI) role on the Delegation of Tasks Log (DTL).  

Alliance A 222001  
15 
Version Date  09/14/22  Update #02  In addition, all investigators acting as the Site -Protocol PI (investigator listed on the IRB 
approval), consenting/treating/drug shipment investigator in OPEN, or as the C I on the DTL 
must be rostered at the enrolling site with a participating organization.  
Additional information is located on the CTEP website at 
 For questions, please contact [CONTACT_182613]  
4.2 CTSU Site Registration Procedures  
Permission to view and download this protocol and its supporting documents is restricted and is 
based on person and site roster assignment housed in the CTSU Regulatory Support System 
(RSS).  
This study is supported by [CONTACT_6818] (CTSU) . 
IRB Approval   
For CTEP and Division of Cancer Prevention (DCP) studies open to the National Clinical Trials 
Network (NCTN) and NCI Community Oncology Research Program (NCORP) Research B ases 
after March 1, 2019, all U.S. -based sites must be members of the NCI Central Institutional 
Review Board (NCI CIRB). In addition, U.S. -based sites must accept the NCI CIRB review to 
activate new studies at the site after March 1, 2019. Local IRB review  will continue to be 
accepted for studies that are not reviewed by [CONTACT_194324], or if the study was previously open at 
the site under the local IRB. International sites should continue to submit Research Ethics Board 
(REB) approval to the CTSU Regulatory Offi ce following country -specific regulations.  
Sites participating with the NCI CIRB must submit the Study Specific Worksheet for Local 
Context (SSW) to the CIRB using IRBManager to indicate their intent to open the study locally. 
The NCI CIRB’s approval of t he SSW is automatically communicated to the CTSU Regulatory 
Office, but sites are required to contact [CONTACT_669089]. Site preferences can be set at the network or protocol level. 
Questions about establishing site preferences can be addressed to the CTSU Regulatory Office 
by [CONTACT_669090] , the Site -Protocol Principal Investigator (PI) (i.e. the investigator on the IRB/REB 
approval) must meet the following criteria in order for the processing of the IRB/REB 
approval record to be completed:  
• Holds an active CTEP status;  
• Active status at the site(s) on the IRB/REB approval ( applies to US and Canadian sites 
only) on at least one participating organization’s roster;  
• If using NCI CIRB, active on the NCI CIRB roster under the applicable CIRB Signatory 
Institution(s) record;  
• Includes the IRB nu mber of the IRB providing approval in the Form FDA 1572 in the 
RCR profile;  
• Lists all sites on the IRB/REB approval as Practice Sites in the Form FDA 1572 in the 
RCR profile; and  
• Holds the appropriate CTEP registration type for the protocol.  
 

Alliance A 222001  
16 
Version Date  09/14/22  Update #02  4.2.1 Addit ional Requirements  
Additional site requirements to obtain an approved site registration status include:  
• An active Federal Wide Assurance (FWA) number;  
• An active roster affiliation with the Lead Protocol Organization (LPO) or a Participating 
Organization (PO);  
• An active roster affiliation with the NCI CIRB roster under at least one CIRB Signatory 
Institution (US sites only); and  
• Compliance with all proto col-specific requirements (PSRs).  
4.2.[ADDRESS_903780]   to review study requirements and 
procedures . See Section 14.1  for instructions regarding how to be added to this trial.  
4.2.3 Download ing Site Registration Documents  
Download the site registration forms from the protocol -specific page located on the 
CTSU members’ website. Permission to view and download this protocol and its 
supporting documents is restricted to institutions and its asso ciated investigators and staff 
on a participating roster. To view/download site registration forms:   
• Log in to the CTSU members’ website  using your CTEP -IAM 
username [CONTACT_2383];  
• Click on Proto cols in the upper left of the screen:  
o Enter the protocol number in the search field at the top of the protocol tree; or  
o Click on the By [CONTACT_56124], then select [Alliance] , 
and protocol number [A222001] . 
Click on Documents, Protocol Related Documents, and use the Document Type  filter and 
select Site Registration to download and complete the forms provided. (Note: For sites 
under the CIRB, IRB data will load automatically to the CTSU.)  
4.2.4  Submitting Regulatory Documents  
Submit required forms and documents to the CTSU Regulatory Office using the 
Regulatory Submission Portal on the CTSU members’ website.  
To access the Regulatory Submission Portal log in to the CTSU members’ website, go to 
the Regulatory  section and select Regulatory Submission . 
Institutions with patients waiting that are unable to use the Regulatory Submission 
Portal should alert the CTSU Regulatory Office immediately by [CONTACT_61529]: 
 in order to receive further 
instruction and support.  
4.2.5 Checking your s ite’s registration s tatus  
Site registration status may be verified on the CTSU members’ website.  
• Click on Regulatory at the top of the screen;  

Alliance A 222001  
17 
Version Date  09/14/22  Update #02  • Click on Site Registration; and 
• Enter the sites 5-character CTEP Institution Code and click on Go.  
o Additional filters are available to sort by [CONTACT_1738], Registration Status, 
Protocol Status, and/or IRB Type.  
Note: The status shown only reflects institution al compliance with site registration 
requirements as outlined within the protocol . It does not reflect compliance with protocol 
requirements for individuals participating on the protocol or the enrolling investigator’s 
status with NCI or their affiliated n etworks . 
4.[ADDRESS_903781] be aware of the neoplastic nature of his/her disease and willingly consent 
after being informed of the procedure to be followed, the experimental nature of the 
therapy, alternatives, potential benefits, side -effects, risks, and discomforts. Current human 
protection committee approval of this protocol and a consent form is required prior to 
patient consent and registration.  
This study includes the use of the mandato ry pati ent completed measures . The patient 
reported measures are available in English . Participation in Alliance A [ADDRESS_903782] form (located under the site registration documents section of the A 222001  
CTSU web site) and submitting it through the CTSU regulatory portal . Samples of the 
booklets are found i n Appendices I-VII, which are to be used for reference and IRB 
submission only. They are not to be used for patient completion.  
4.4 Patient  Enrollment ( registration/random ization procedures  (Step 1) ) 
The Oncology Patient Enrollment Network (OPEN) is a web -based registration system 
available on a 24/7 basis. OPEN is integrated with CTSU regulatory and roster data and 
with the LPOs registration/randomization systems or the Th eradex Interactive Web 
Response System (IWRS) for retrieval of patient registration/randomization assignment. 
OPEN will populate the patient enrollment data in NCI’s clinical data management 
system, Medidata Rave.  
Requirements for OPEN access:   
• A valid CTEP -IAM account ; 
• To perform enrollments or request slot reservations: Must be on an LPO roster, 
ETCTN corresponding roster, or participating organization roster with the role of 
Alliance A 222001  
18 
Version Date  09/14/22  Update #[ADDRESS_903783] hold a min imum of an Associate Plus (AP) registration 
type;  
• If a Delegation of Tasks Log (DTL) is required for the study, the registrars must hold 
the OPEN Registrar task on the DTL for the site; and  
• Have an approved site registration for the protocol prior to patie nt enrollment.  
 
To assign an Investigator (IVR) or Non -Physician Investigator (NPI[INVESTIGATOR_6731]) as the treating, 
crediting, consenting, drug shipment (IVR only), or receiving investigator for a patient 
transfer in OPEN, the IVR or NPI[INVESTIGATOR_669066]’s IRB 
approval on their Form FDA [ADDRESS_903784] be assigned the appropriate OPEN -related tasks on the DTL.  
    Prior to accessing OPEN, site staff should verify the following:  
• Patient has  met all eligibility criteria within the protocol stated timeframes; and  
• All patients have signed an appropriate consent form and Health Insurance Portability 
and Accountability Act (HIPAA) authorization  form  (if applicable).  
Note:   The OPEN  system will p rovide the site with a printable confirmation of registration and 
treatment information.  You may print this confirmation for your records.   
Access OPEN at or from the OPEN link on the CTSU members ’ website. 
Further instructional information is in the OPEN section of the CTSU website at 
For any additional questions, contact [CONTACT_110694]  
 
4.5 Stratification Factors and Treatment Assignments  
The randomization routine is found in Section 13  (Statistical Considerations).  
4.5.1 Stratification Factors  
Stratification factors include:  
[IP_ADDRESS] Daily hot flash frequency at baseline:  4 to 9 hot flashes per day versus 10 
or more hot flashes per day  
[IP_ADDRESS] Hot flash duration at baseline : less than 9  months versus 9 or more months , 
and 
[IP_ADDRESS] Number of prior hot flash therapi[INVESTIGATOR_014] (0 versus 1 or more) . 
4.5.2 Treatment Assignments  
The factors defined in Section 4.5 .1 will be used as stratification factors.  
After the patient has been registered into the study, the values of the stratification factors 
will be recorded, and the patient w ill be assigned to one of the following treatment groups 
using the Pocock and Simon dynamic allocation procedure  [41] which balances the 
marginal distributions of the stratification factors between the treatment groups.   
• Oxybutynin: 2. 5 mL oral BID Days 8 through 49 (total of 42 days)  
• Oxybutynin: 5 mL  oral BID Days 8 through 49 (total of 42 days)  
• Placebo: 2.5 mL oral BID Days 8 through 49 (total of 42  days)  
• Placebo: 5 mL oral BID Days 8 through 49 (total of 42 days)  

Alliance A 222001  
19 
Version Date  09/14/22  Update #02  Note: Oxybutynin c oncentration = 1mg/mL.  
4.[ADDRESS_903785] will notify the designated unblinded data manager/nurse/pharmacist at the patient’s 
institution. The name [CONTACT_669134] [CONTACT_669091].  This contact [CONTACT_669092] n form as the person completing the form. The OPEN 
registration form should provide the source of communication, either fax or e -mail, and the 
appropriate contact [CONTACT_3031]. The Registration Specialist will then communicate the 
treatment assignment “ Oxyb utynin 2.5 mL , Placebo 2.5 mL, Oxybutynin 5 mL  or Placebo 5 
mL” to designated contact [CONTACT_669093]’s institution.  
Once the treatment assignment has been communicated, the designated contact [CONTACT_669094].  
The dose will be prepared and labeled as “ oxybutynin/placebo ” so that the contents are not 
discernible to the person administering the tr eatment.  
The pharmacist or designated contact [CONTACT_669095]. The pharmacist or designated contact 
[CONTACT_669096] i ndicate the identity of the patient and their 
corresponding study medication code number.  
4.7 Cross-Over  Re-registration (step 2) Procedures  
Patients who complete [ADDRESS_903786] call the Alliance Registration Office (507 -284-4130) during regular business hours to 
find out if the patient was receiving oxybutynin or placebo.  Site staff must  ensure that the 
questionnaires associated with the initial cycle of treatment have been completed and sent to the 
study staff by  [CONTACT_669097], as these are related to the 
assessment of the primary endpoint of the study.  
If the patient was receiving placebo, he will be allowed to cross over and receive oxybutynin at 
the discretion of the treating physici an. 
Patients who choose to ent er the cross -over phase will be re -registered as follows:   
1. Site staff will log into the OPEN registration system and select the appropriate patient.  
2. Then select the next registration step.  (Step 2)  
3. Complete the OPEN Enrollment Form for the patient to be re -registered for the 
continuation phase . The patient will be re -registered to oxybutynin 2.5 or 5.0 mL, 
equivalent to whichever dose of placebo the patient was receiving prior to unblinding . 
4. Verify t he patient turned in their questionnaires for the initial cycle of treatment, yes/no.  
5. Once the re-registration to the crossover phase  is successfully completed , a confirmati on 
email will be sent to the CRP . 
If assistance is needed with this process, contac t the Alliance Registration Office at 
 
Following re -registration,  the designated contact [CONTACT_669098] s/he can 
prepare drug for delivery to the patient . Patient should be told that he may need to come back to 
the clinic to pi[INVESTIGATOR_669067].   

Alliance A 222001  
20 
Version Date  09/14/22  Update #02  5.0 STUDY  CALENDAR  
Pre-study Testing Intervals : 
The pre -study testing intervals are guidelines only. Laboratory and clinical parameters during 
treatment are to be followed using individual institutional guidelines and the best clinical judgment 
of the responsible physician. It is expected that patients on this study will be cared for by [CONTACT_669099].  
When calculating days of tests and measurements, th e day a test or measurement is done is considered 
Day 0. Therefore, if a test were done on a Monday, the Monday one week later would be considered 
Day 7.  
To be completed ≤ 60 DAYS  before registration:  History and physical.   
 Prior to 
Registration  Baseline 
booklets  
(Days 1 -7) Daily during 
treatment  
(Days 8 -49) 
 End of each week 
of treatment  
 
Tests & Observations      
History and physical , 
including V ital signs   X    
Height, Weight, ECOG PS  X    
Baseline Symptom 
Documentation ( Appendix 
II)  X (1)    
International Prostate 
Symptom Score - 
(Appendix III ) X   X 
Hot Flash Diary  
(Appendix IV )   X  
Symptom Experience 
Questionnaire  
(Appendix V)  A (1)   X 
Hot Flash Related Daily 
Interference Scale 
(HFRDIS) ( Appendix V I)  A (1)   B(2) 
Telephone Contact [CONTACT_669100]  
(Appendix VI I)    X (2)  
1 Nurse/research coordinator should call the patient, to  remind him to send in the baseline 
questionnaire  booklets to the site , which are required to be completed prior to start of study 
treatment .  
2 All patients will receive weekly phone calls from study staff (nurse or research coordinator), to 
document compliance with st udy drug, encourage completion of patient questionnaires, assess 
adverse events, and address any patient concerns or problems. They will also remind the patient to 
return the completed questionnaire booklets. For patients who choose to cross over, nurse ph one 
calls will occur weekly to assess adverse events during the unblinded cross over phase. (See 
Section 7.3)  
A To be c ompleted on Day 7.  
B To be completed at the end of Weeks 2, 4 and 6  only (Weeks 3 , 5 and 7  when measured from 
registration) .  
Alliance A 222001  
21 
Version Date  09/14/22  Update #02  6.0 DATA SUBMISSION  
6.1 Data Collection and Submission  
6.1.1  Data submission schedule  
A Data Submission Schedule (DSS)  is available on the Alliance study webpage, within the 
Case Report Forms sect ion. The Data Subm ission Schedule  is also available on the CTSU 
site within the study -specific Case Report Forms folder.  
6.1.[ADDRESS_903787] is a clinical data management system being used for data collection for 
this trial/study. Access to the trial in Rave is controlled through the CTEP -IAM system 
and role assignments.  
Requirements to access Rave via iMedidata:  
• A valid CTEP -IAM account; and  
• Assigned a Rave role on the LPO or PO roster at the enrolling site of: Rave CRA, 
Rave Read Only, Rave CRA ( LabAdmin), Rave SLA, or Rave Investigator.  
Rave role requirements:  
• Rave CRA or Rave CRA (Lab Admin) role must have a minimum of an Associate 
Plus (AP) registration type;  
• Rave Investigator role must be registered as an Non -Physician Investigator (NPI[INVESTIGATOR_6731]) 
or Investigator (IVR); and  
• Rave Read Only role must have at a minimum an Associates (A) registration type.  
Refer to  for registration types 
and documentation required.  
 
This study has a Delegation of Tasks Log (DTL). Therefore, those requiring write access 
to Rave must also be assigned the appropriate Rave tasks on the DTL.  
 
Upon initial site registration ap proval for the study in Regulatory Support System (RSS), 
all persons with Rave roles assigned on the appropriate roster will be sent a study invitation 
email from iMedidata.  To accept the invitation, site staff must either click on the link in 
the email or  log in to iMedidata via the CTSU members’ website  under Data Management 
> Rave Home  and click to accept  the invitation in the Tasks  pane located in the upper right 
corner of the iMedidata screen.  Site staff will not be able to access the study in Rave un til 
all required Medidata and study specific trainings are completed.  Trainings will be in the 
form of electronic learnings (eLearnings) and can be accessed by [CONTACT_669101]. If an 
eLearning is required for a study and has not yet been taken, the link to the eLearning will 
appear under the study name [CONTACT_669135]; once the successful completion of the eLearning ha s been recorded, access to the 
study in Rave will be granted, and a Rave EDC  link will replace the eLearning link under 
the study name.   
Site staff that have not previously activated their iMedidata /Rave account at the time of 
initial site registration approval for the study in RSS will receive a separate invitation 
from iMedidata to activate their account.  Account activation instructions are located on 

Alliance A 222001  
22 
Version Date  09/14/22  Update #[ADDRESS_903788] resource materials 
(Medidata Account Activation and Study Invitation Acceptance). Additional information 
on iMedidata/Rave is available on the CTSU members’ website in the Data Management 
> Rave section at or by [CONTACT_669102]    
6.1.3  Data Quality Portal  
The Data Quality Portal (DQP) provides a central location for site staff to 
manage unanswered queries and form delinquencies, monitor data quality and 
timeliness, generate reports, and review metrics.  
The DQP is located on the CTSU members’ website under Data Management. 
The Rave Home section displays a table provid ing summary counts of Total 
Delinquencies and Total Queries. DQP Queries, DQP Delinquent Forms, DQP 
Form Status and the DQP Reports modules are available to access details and 
reports of unanswered queries, delinquent forms, forms with current status and 
timeliness reports. Review the DQP modules on a regular basis to manage 
specified queries and delinquent forms.  
The DQP is accessible by [CONTACT_278623] a site and have access to 
the CTSU website.  Staff that have Rave study access can access  the Rave study 
data using a direct link on the DQP.  
To learn more about DQP use and access, click on the Help icon displayed on the 
Rave Home, DQP Queries, DQP Delinquent Forms, DQP Form Status, and DQP 
Reports modules.  
 
6.2 Submission of Patient Complete d Measures  
Patient -completed questionnaire booklets for this study are to be ordered prior to the registration 
of an y patients (see Section 4.3). Samples of questionnaire booklets are availab le in Appendices  
I-VII for reference and IRB submission only. They are not to be used for patient completion. 
Booklets must be given to patients to complete and patients should be instructed to return the 
booklets to site staff either in pers on or by [CONTACT_669103] l enter patient responses into 
Medidata Rave. At visits in which booklets are to be completed, the booklet should be given to 
the patient before any discussion of the patient’s health status or test results. The PRO 
submission schedule is provided in the S tudy Calendar.  
Weekly Booklets:  Six booklets to be completed weekly must be given to patients to complete 
at home and patients should be instructed to return the booklets by [CONTACT_669104]. Institutions must provide patien ts with 
sufficient self -addressed stamped envelopes for this purpose. Site staff will enter patient 
responses into Rave upon receipt of the completed booklets.  
Verbal administration of the measures for visually impaired patients is permitted if the verbal 
administration of the measure is conducted in a language understandable to the patients.  
6.2.1 Patient Language Considerations  
The patient reported measures are available in English. Participation in Alliance A 222001  
is restricted to patients who are able to speak, understand and read English . Ad -hoc 
translation of patient -completed measures is not permitted.   
  

Alliance A 222001  
23 
Version Date  09/14/22  Update #02  7.0 TREATMENT  PLAN/INTERVENTION  
Protocol treatment is to begin ≤ [ADDRESS_903789]  (see Section 4.6 ) at 
the institution will be informed of the patient’s randomization , so that they may prepare oxybutynin 
or placebo for delivery to the patient (see Section 10 .0). 
The placebo arms  will be half the size as the oxybutynin arms , as they will be combined to have a 
placebo group with the same number of patients as the two different dose groups. This allows all 
patients to be blinded as to whether they are receiving active drug or a placebo.  
Patients will  be assigned to one of the following treatment groups , and continue to receive  treatment 
for 6 weeks (i.e., 42 days):  
 Days 1 -7 Days 8 -49 
Oxybutynin 2.5 mL   Patients on all arms will be 
asked to complete 
questionnaires as baseline 
symptom documentation on 
Days 1 -7, before starting 
study treatment on Day 8.  Oxybutynin 2.5 mL*  PO twice a day  
Placebo 2.5 mL  Placebo 2.5 mL* PO twice a day  
Oxybutynin  5 mL  Oxybutynin 5.0 mL * PO twice a day  
Placebo  5.0 mL  Placebo 5.0 mL* PO twice a day  
* Note that the concentration of oxybutynin is [ADDRESS_903790] seven days of the 
study , but to complete their daily questionnaires (Baseline Symptom Documentation – 
Appendix II ) during this baseline period. At the end of the week, patients will complete 
Symptom Experience Questionnaire ( Appendix  V) and Hot Flash Related Daily Interference 
Scale ( Appendix V I). 
7.2 Oxybutynin/Placebo  
Beginning on Day 8 of the study, and f or the subsequent six weeks, patients will be instructed 
to take their study medication as illustrated below.  
• Oxybutynin: 2.5 mL oral BID Days 8 through 49 (total  of 42 days)  
• Placebo: 2.5 mL oral BID Days 8 through 49 (total of 42  days)  
• Oxybutynin: 5.0 mL oral BID Days 8 through 49 (total of 42 days)  
• Placebo: 5.0 mL oral BID Days 8 through 49 (total of 42 days)  
7.[ADDRESS_903791] scheduled day of the study treatment .  It should be assure d 
that the patient has completed  his questionnaires. Then the patient may be unblinded per the 
procedures described in Section 8.3 .  
Alliance A 222001  
24 
Version Date  09/14/22  Update #02  If the patient was receiving placebo, he may choose to crossover to oxybutynin 2.5 or 5.0 mL, 
equivalent to whichever dose of placebo the patient was receiving prior to unblinding. This 
crossover will require a second registration (see Section 4.7  for re -registration instructions).  The 
duration of treatment for patients who crossover will be [ADDRESS_903792] support, antibiotic treatment, and treatment of other newly diagnosed or 
concurrent medical conditions.  All blood pr oducts and concomitant medications such as 
antidiarrheals, analgesics, and/or antiemetics received from the first day of study 
treatment administration until 30 days after the final dose will be recorded in the medical 
records.  
8.1.3 Treatment of the patient’s cancer should not be influenced by t his study. If the 
patient  stops ADT while participating in the study , it should be recorded on the study 
forms.  
8.2 Dose Modifications  
Dose modifications to the patient’s cancer treatment are up to the discreti on of the treating 
physician.  During participation in the study, if the patient develops any symptoms attributed to 
the drug that are considered to be of unacceptable severity by [CONTACT_5363]/or physician, 
oxybutynin /placebo doses will be adjusted as f ollows:  
Dose modifications for adverse events  
Low Dose  
(2.5 mL BID)  Maintain prescribed dose, but decrease frequency from BID to once 
daily.  
If symptoms are still unacceptable by [CONTACT_5363]/or physician, 
drug will be discontinued and patient will be taken off study.  
High Dose  
(5.0 mL BID)  If toxicity occurs, decrease dose from [ADDRESS_903793], decrease dose from 2.5 mL BID to 2.5 mL once 
daily. If symptoms are still unacceptable by [CONTACT_5363]/or 
physician , the drug will be discontinued and patient will be as ked to 
complete questionnaires to date and then be taken off study.  
Urinary retention :  For patients on both doses, i f at any time during treatment, the patient 
develops severe urinary symp toms , he should  immediately discontinue study treatment and get 
a post void r esidual ultrasound assessment as  clinically indicated.  
  
Alliance A 222001  
25 
Version Date  09/14/22  Update #[ADDRESS_903794] discontinue protocol therapy.  
8.3.1  Emergency Unblinding Procedures  
Examples of emergencies include 1) a life -threatening unexpected adverse event  that is at 
least possibly related to the investigational agent and for which unblinding would influence 
treatment decisions; or 2) medication error, such as accidental overdose. Expected adverse 
events are listed in the “Toxicities” section below.  
Contac t the Alliance Executive Officer on call by [CONTACT_669105]:  
• Allian ce study ID (i.e., “A 222001 ”)  
• Alliance patient ID number (e.g., “999999”)  
• Patient initials (e.g., “L,F ,M”)  
• Institution name  
• Name [CONTACT_669136]  
• Name [CONTACT_3669] [CONTACT_280082]  
• Name [CONTACT_3669] [CONTACT_280083]  
• Reason for emergency unblinding  
Please remember that emergency unblinding request may be authorized only by [CONTACT_280084], and emergency unblinding applies only if unblinding would influence 
management of the medical situation. After the Executive Officer deems unblinding is 
warranted, the treatment assignment will be provided to the contac t person at the treating 
site. 
8.3.2  Protocol -specified unblinding —Crossover Unblinding at end of treatment  
The steps for unblinding a patient upon completion of study treatment are as follows:  
1. Patient has  completed [ADDRESS_903795].  
3. Site calls the registration office to unblind the patient; registration office confirms 
receipt of the end of treatment form with statistics and data center in order to 
communicate patient treatment assignme nt to site.  
Contact [CONTACT_669106]. 
Upon confirmation by [CONTACT_669107] (or designee) that the criteria for unblinding  
have been met, the treatment assignment may be unblinded. No Al liance Executive Officer 
(or designee) approval is required.   
  

Alliance A 222001  
26 
Version Date  09/14/22  Update #[ADDRESS_903796] be described and graded using the 
terminology and grading categories defined in the NCI’s Common Terminology Criteria for Adverse 
Events (CTCAE), Ve rsion 5.0. The CTCAE is available at 
 Attri bution to protocol 
treatment for each adverse event must be determined by [CONTACT_669108]. Please refer the NCI Guidelines: Adverse Event Reporting Requirements for further details 
on AE reporting procedures.  
9.1 Routin e Adverse Event Reporting  
Adverse event data collection and reporting, which are required as part of every clinical trial are 
done to ensure the safety of patients enrolled in the studies as well as those who will enroll in 
future studies using similar age nts. Adverse events are reported in a routine manner at scheduled 
times according to the study calendar in Section 5.0 .  
9.1.1 Solicited adverse events  
There are no additional solicited adverse events for this trial.  
9.2 CTCAE Routine Reporting Requirements  
The following table outlines the combinations of time points, grades and attributions of AEs that 
require routine reporting to the Alliance Statistics and Data Center. Questions about routine 
reporting should be di rected to the Data Manager.  
Combinations of CTCAE Grade & Attribution Required for Routine AE Data Submission on 
Case Report Forms (CRFs)  
Attribution  Grade 1  Grade 2  Grade 3  Grade 4  Grade 5  
Unrelated    a a a 
Unlikely    a a a 
Possible   a a, b a, b a, b 
Probable   a a, b a, b a, b 
Definite   a a, b a, b a, b 
a) Adverse Events: Other CRF  - Applies to AEs occurring between registration and within 
30 days of the patient’s last treatment date, or as part of the Clinical Follow -Up Phase.  
b) Adverse Events: Late CRF  - Applies to AEs occurring greater than 30 days after the 
patient’s last treat ment date.  
  

Alliance A 222001  
27 
Version Date  09/14/22  Update #02  9.3 Expedited Adverse Event Reporting (CTEP -AERS)  
Investigators are required by [CONTACT_669109]. The descriptions and grading scales found in the NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for A E reporting.  The CTCAE 
is identified and located on the CTEP website at: 
 All appropriate 
treatment areas should have access to a copy of the CTCAE. All reactions determined to be 
“reportable” in an expedited manner must be reported using the Cancer Therapy Evaluation 
Program Adverse Event Reporting System (CTEP -AERS ). 
For further information on the NCI requirements for SAE reporting, please refer to the ‘NCI 
Guidelines for Investigators: Adverse Event Reporting Requirements’ document published by 
[CONTACT_6812].  
Note:   All deaths on study require both routine and expedited  reporting regardless of causality.  
Attribution to treatment or other cause should be provided.  
9.3.1 Late Phase 2 and Phase 3 Studies: Expedited Reporting Requirements for Adverse 
Events that Occur on Studies under an IND/IDE within [ADDRESS_903797] 
Administration of the Investigational Agent/Intervention1, 2 
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)  
NOTE:   Investigators MUST  immediately report to the sponsor (NCI) ANY Serious Adverse Events, whether or not 
they are considered related to the investigational agent(s)/intervention (21 CFR 312.64)  
An adverse event is considered serious if it results in ANY  of the following outcomes:   
1) Death  
2) A life -threatening adverse event  
3) An adverse event that results in inpatient hosp italization or prolongation of existing hospi[INVESTIGATOR_272] ≥ 24 
hours  
4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions  
5) A congenital anomaly/birth defect.  
6) Important Medical Events (IME) tha t may not result in death, be life threatening, or require hospi[INVESTIGATOR_6721], based upon medical judgment, they may jeopardize the patient or 
subject and may require medical or surgical intervention to prevent one of the outcom es listed in this 
definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6).  
 
ALL SERIOUS  adverse events that meet the above criteria MUST  be immediately reported to the NCI via electronic 
submission within the timeframes detailed in the table below.  
Hospi[INVESTIGATOR_317] 1 
Timeframes  Grade 2 
Timeframes  Grade 3 Timeframes  Grade 4 & 5 
Timeframes  
Resulting in 
Hospi[INVESTIGATOR_059]  
≥ 24 hrs 10 Calendar Days  
24-Hour 5 
Calendar Days  Not resulting in  
Hospi[INVESTIGATOR_059]  
≥ 24 hrs Not required  10 Calendar Days  
NOTE:   Protocol specific exceptions to expedited reporting of serious adverse events are found in the Specific 
Protocol Exceptions to Expedited Reporting (SPEER) portion of the CAEPR  
Expedited AE reporting timelines are defined as:  
o “24-Hour; 5 Calendar Days” - The AE must initially be submitted electronically within 24 hours of 
learning of the AE, followed by a complete expedited report within 5 calendar days of the initial 24 -
hour report.  
o “10 Calendar Days” - A complete expedited report on the AE must b e submitted electronically within 
[ADDRESS_903798] administration of investigational 

Alliance A 222001  
28 
Version Date  09/14/22  Update #02  agent/intervention and have an attribution of possible, probable, or definite require reporting as follows:  
Expedited 24 -hour notification followed by [CONTACT_6794] 5 calendar days for:  
• All Grade 4, and Grade 5 AEs  
Expedited 10 calendar day reports for:  
• Grade 2 adverse events resulting in hospi[INVESTIGATOR_318]  
• Grade [ADDRESS_903799] whole day, after the agent/intervention was last administered.  Footnote “1” above 
applies after this reporting period.  
Effective Date:  May 5, 2011  
 
9.3.2  Expedited  AE reporting timelines defined  
• “24 hours; 5 calendar days” – The investigator must initially report the AE via 
CTEP -AERS ≤ 24 hours of learning of the event followed by a complete CTEP -
AERS report ≤ 5 calendar days of the initial 24 -hour re port. 
• “10 calendar days” - A complete CTEP -AERS report on the AE must be submitted 
≤ 10 calendar days of the investigator learning of the event.  
Any medical event equivalent to CTCAE grade 3, 4, or 5 that precipi[INVESTIGATOR_99204] 
(or prolongation of e xisting hospi[INVESTIGATOR_059]) must be reported regardless of attribution and 
designation as expected or unexpected with the exception of any events identified as 
protocol -specific expedited adverse event reporting exclusions (see below).  
Any event that results in persistent or significant disabilities/incapacities, congenital 
anomalies, or birth defects must be reported via CTEP -AERS if the event occurs following 
treatment with an agent under an  IND.  
Use the NCI protocol number and the protocol -specific patient ID provided during trial 
registration on all reports.  
9.3.3  Additional Instructions or Exclusion s to CTEP -AERS Expedited Reporting 
Requirements  
All adverse events reported via CTEP -AERS (i.e., serious adverse events) should also be 
forw arded to your local  IRB.  
Alliance A 222001 uses a drug under a n Alliance  IND. The reporting requirements for 
investigational agents under a CTEP IND should be followed for all agents (any arm) in 
this trial.  
Treatment expected adverse events include those listed in Section 10.0  and in the package 
insert.  
CTEP -AERS reports should be submitted electronically.  
Death  
Death due to progressive disease should be reported as Grade 5 “ Disease  progression ” in 
the system organ class (SOC)  “General disorders and administration site conditions .” 
Evidence that the death was a manifestation of underlying disease (e.g., radiological 
changes suggesting tumor growth or progression: clinical deteriorati on associated with a 
disease process) should be submitted.  
Any death occurring within [ADDRESS_903800] dose, regardless of attribution to the 
investigational agent/intervention requires expedited reporting within 24 hours.  
Alliance A 222001  
29 
Version Date  09/14/22  Update #[ADDRESS_903801] dose of the investigational 
agent/intervention requires expedited reporting within 24 hours only if it is possibly, 
probably, or definitely related to the investigational agent/intervention.  
New Malignancies  
All new malignancies  must be reported via CTEP -AERS whether or not they are thought 
to be related to either previous or current treatment. All new malignancies should be 
reported, i.e. solid tumors (including non -melanoma skin malignancies), hematologic 
malignancies, myelodys plastic syndrome/acute myelogenous leukemia, and in situ tumors.  
Whenever possible, the CTEP -AERS reports for new malignancies should include tumor 
pathology, history or prior tumors, prior treatment/current treatment including duration, 
any associated risk factors or evidence regarding how long the new malignancy may have 
been present, when and how the new malignancy was detected, molecular characterization 
or cytogenetics of the original tumor (if available) and of any new tumor, and new 
malignancy treatment and outcome, if available.  
Secondary Malignancy  
A secondary malignancy is a cancer caused by [CONTACT_437] a previous malignancy (e.g., 
treatment with investigational agent/intervention, radiation or chemotherapy). A secondary 
malignancy is not considered a metastasis of the initial neoplasm.  
CTEP requires all secondary malignancies that occur following treatment with an agent 
under an NCI IND/IDE be reported via CTEP -AERS. Three options are available to 
describe the event:  
• Leukemia seco ndary to oncology chemotherapy (e.g., acute myelocytic leukemia 
[AML])  
• Myelodysplastic syndrome (MDS)  
• Treatment -related secondary malignancy  
Any malignancy possibly related to cancer treatment (including AML/MDS) should also 
be reported via Rave .  
Secon d Malignancy  
A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT 
a metastasis from the initial malignancy).  Second malignancies require ONLY routine 
reporting unless otherwise specified.  
10.0 DRUG INFORMATION  
10.1 Oxybu tynin Chloride Oral Syrup (Ditropan)  
IND: Alliance A222001 uses Oxybutynin  under an Alliance IND.  
Procurement  
Oxybutynin  Chloride 5mg/5 mL  oral syrup (473 mL)  and ORA -Sweet® Solution (473 mL)  stock 
bottles will be provided and shipped by [CONTACT_669110] .  
After receiving IRB approval for this study, each participating institution will order a starter 
supply of three  bottles of oxybutynin oral syrup and two bottles of ORA -Sweet® solution  from 
McKesson Clinical Research Services  by [CONTACT_669111]/Return Form to:  
Alliance A 222001  
30 
Version Date  09/14/22  Update #02   
 
The A222001 Oxybutynin /Placebo Order Form  can be found on the A2220 [ADDRESS_903802] patien t is treated at the institution, any expi[INVESTIGATOR_669068].  
Preparation  
The designated unblinded person at each institution will transfer either oxybutynin chloride 5 
mg/5 mL oral syrup or OR A-Sweet® solution into one 16 oz amber bottles based on the patient’s 
treatment assignment.  This should be a sufficient supply for the entire 42 days of treatment.  
The bottles will be labeled “oxybutynin 5 mg/5 mL or placebo solution”.  A maximum 
expi[INVESTIGATOR_669069] [ADDRESS_903803] confirm that sufficient in-date 
supply  is available  for the duration of intervention.  
 
Below is the labe l template for the blinded phase:  
RX#___________________DATE_________________  
PT NAME ____________________________________  
INVESTIGATOR ______________________________  
 
Study A222001: Take by [CONTACT_6816] 42 days as directed by [CONTACT_3476].  
 
Oxybutynin 5mg/5ml or Placebo Oral Syrup  
Dispense: 4 73ml       Expi[INVESTIGATOR_5952]:  ____________  
Store at room temperature, 15 – 30 °C (59 to 86°F)  
Sponsor:  
 
CAUTION: NEW DRUG -LIMITED BY [CONTACT_949] (OR UNITED STATES) LAW TO 
INVESTIGATIONAL USE ONLY  
 
For patients who are re -registered to the cross over phase, the bottles need to be open label 
“Oxybutynin 2.5 or 5.0 mL”  depending on which dose the  patient is assigned to receive.  
 

Alliance A 222001  
31 
Version Date  09/14/22  Update #02  Below is the label te mplate for the cross over phase:  
 
RX#___________________DATE_________________  
PT NAME ____________________________________  
INVESTIGATOR ______________________________  
 
Study A222001: Take by [CONTACT_669112] 42 days as directed by [CONTACT_3476].  
 
Oxybutynin 5mg/5ml Oral Syrup  
Dispense: 4 73ml       Expi[INVESTIGATOR_5952]:  ____________  
Store at room temperature, 15 – 30 °C (59 to 86°F)  
Sponsor:  
 
CAUTION: NEW DRUG -LIMITED BY [CONTACT_949] (OR UNITED STATES) LAW TO 
INVESTIGATIONAL USE ONLY  
 
Drug Accountability  
Drug accountability logs mu st be kept for the oxybutynin 5 mg/5 mL oral syrup and the ORA -
Sweet® oral solution . 
Investigator Brochure Availability  
The current version of the package insert  for the agents will be accessible to site i nvestigators 
and research staff through the Alliance office.  
Availability  
Oxybutynin oral syrup is availab le as 5 mg/ 5mL concentration with raspberry  flavor.  The 
solution contains citric acid, D&C Yellow No 10, FD&C Blue No 1, glycerin, liquid sugar, 
methylparaben, propylene glycol, sodium citrate, and sorbitol solution .   
Storage and Stability  
Store at  Controlled Room Temperature, 15 –30°C (59 –86°F) . 
Administration  
Oxybutynin /placebo will  be administered at a dosage of either 2.5mg/2.5ml or 5mg/5ml two 
times daily. Study medication can be taken with or without food.   
Drug Interactions  
The concomitant use  of oxybutynin with other anticholinergic drugs or with other agents 
which produce dry mouth, constipation, somnolence (drowsiness), and/or other 
anticholinergic -like effects may increase the frequency and/or severity of such effects.  
Anticholinergic agent s may potentially alter the absorption of some concomitantly 
administered drugs due to anticholinergic effects on gastrointestinal motility. Anticholinergic 
agents may also antagonize the effects of prokinetic agents, such as metoclopramide.  
Mean oxybutyn in plasma concentrations were approximately 3 to 4 fold higher when 
oxybutynin chloride tablets were administered with ketoconazole, a potent CYP3A4 inhibitor.  

Alliance A 222001  
32 
Version Date  09/14/22  Update #02  Other CYP3A4 inhibitors, such as antimycotic agents (e.g., itraconazole and miconazole) or 
macr olide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean 
pharmacokinetic parameters. The clinical relevance of such potential interactions is not 
known. Caution should be used when such drugs are co -administered.  
Pharmacokinetic s  
Time to peak concentration: Oral: 0.89 + 0.[ADDRESS_903804] to the antimuscarinic activity of oxybutynin . 
Bioavailability: The absolute bioavailability of oxybutynin is 6%, although t here is wide 
interindividual variation following oral administration. Food slightly delays absorption and 
increases bioavailability by 25%.  
Metabolism: Hepatic , extensive particularly the CYP3A4 isoenzyme  
Half-life elimination: Normal renal function: 2 -3 hours 
Excretion: Renal, less than 0.1% unchanged as parent compound or as the metabolite N -
desethyloxybutynin.  
Adverse Events  
Consult the package insert for the most current and complete information.  
Following administration of oxybutynin chloride, the following symptoms may occur:  
Cardiovascular: Palpi[INVESTIGATOR_814], tachycardia, vasodilatation  
Dermatologic: Decreased sweating, rash  
Gastrointestinal/Genitourinary: Constipation, decreased gastrointestinal motility, dry mouth, 
nausea, urinary hesitance and retention  
Nervous System: Asthenia, dizziness, drowsiness, hallucinations, insomnia, restlessness  
Ophthalmic: Amblyopia, cycloplegia, decreased lacrimation, mydriasis  
Other: Impotence, suppression of la ctation  
Nursing Guidelines  
1. Use extreme caution when oxybutynin is administered with any other anticholinergic 
agents as increased side effects can occur ( i.e. dry mouth, constipation, somnolence).  
2. Instruct patients to report any palpi[INVESTIGATOR_669070] a to the study team.  
3. Patients may experience rash. Inform patients to report skin changes to the study team.  
4. Warn patients that they may have decreased sweating abilities. They should use caution 
if out in the heat and to avoid becoming overheated.  
5. Gastro intestinal effects can be seen including constipation, decreased GI motility, 
nausea, vomiting, and dry mouth. Treat symptomatically and monitor for effectiveness.  
6. Warn patients of possible urinary hesitation and retention. If patient has difficulty 
voidin g they should report this to the study team immediately.  
7. Patients may experience neurologic side effects including dizziness, hallucinations, 
drowsiness and/or insomnia. Instruct patients to use caution when operating a vehicle 
or other activities that req uire close attention until they know how they respond to agent.  
Alliance A 222001  
33 
Version Date  09/14/22  Update #02  8. Effects on the eye can  include amblyopia (lazy eye), cycloplegia (paralysis of ciliary 
muscle -leading to inability to focus on close objects), decreased tears and mydriasis 
(abnormal pupil dil ation).  Instruct patient to report any of these to the study team.  
9. Warn men that this agent can cause impotence and suppress lactation in women.  
10.2 Placebo Oral Solution  
Procurement  
Please see ordering instructions in Section 10. 1, for both active agent and placebo.  
The placebo for this study will be ORA -Sweet® SF and ORA -Sweet® .  ORA -Sweet® SF and 
ORA -Sweet® are a berry  citrus flavored  inert syrup vehicle. The ORA -Sweet® SF contains 
purified water , sorbitol, sodium saccharin, xanthan gum, and flavoring.  It is buffered with 
citric acid and sodium phosphate , and preserved with methylparaben , propylparaben, and 
potassium sorbate . ORA -Sweet® SF contains FD&C Red#40 and is sugar -free and alcohol -
free. ORA -Sweet® contains purified water, sucrose, glycerin, sorbitol, and flavoring. It is 
buffered with citric acid and sodium phosphate, and preserved with methylparaben and 
potassium sorbate.   
Storage and Stability  
Store at  Controlled Room Temperature, 15 –30°C (59 –86°F) . Store in original container, 
protected from direct sunlight and moisture.  
  
Alliance A 222001  
34 
Version Date  09/14/22  Update #02  11.0 MEASURES  
Before they start treatment and during the course of study treatment,  patients will be asked to assess 
the severity of their hot flashes (descriptions provided in Appendix I ) and complete a baseline 
symptoms determination (Appendix II)  (Week 1 only) ,  daily  Hot Flash Diaries ( Appendix IV ), along 
with weekly Symptom Experience Questionnaires ( Appendix V). The Hot Flash Related Daily 
Interference Scale (HFRDIS)  (Appendix VI) will be completed prior to in itiation  of and at the 
conclusion of study treatment. All patients will receive weekly phone calls from study staff 
(Appendix V II) to document compliance with study drug, encourage c ompletion of requisite study 
questionnaires,  collect adverse events  and address any patient concerns or problems.  
11.1 Baseline Symptom Determination  (Appendix I I) 
The baseline symptoms determination is completed af ter registration and randomization but 
prior to initiation of study treatment. This form has patients record the number of total hot flashes 
they experience on a daily basis, along with the number of hot flashes according to severity 
(mild, moderate, sever e, or very severe) over the first 7 days of the study period. It is estimated 
that completing the baseline symptom determination will take 3 -5 minutes daily.  Questionnaires 
should be returned to the investigator at the end of the baseline week (week 1) and  at the end of 
treatment (i.e., after the 7th week following study entry).  The patient should be supplied with 
two addressed/stamped envelopes for returning the forms . 
11.2 International Prostate Symptom Score (IPSS) ( Appendix III ) 
This tool has been added to this study at screening and to be completed at the end of every week 
of treatment in response to FDA recommendations to ensure that patients do not have urinary 
retention issues. This is an [ADDRESS_903805] symptoms. It includes questions encompassing incomplete bladder emptying, 
frequent urination, urgency, nocturia, intermittency, weak stream, straining, and quality of life 
related to urinary sympto ms[42]. 
There are robust data to suggest that prostate cancer patients on active surveillance experience 
significantly decreased urinary health relative to men without  prostate cancer. In a cohort 
analysis of 6,000 community dwelling older men, we observed that compared to men without 
prostate cancer, men with prostate cancer on active surveillance (i.e. those who had not 
undergone treatment) reported a significantly di minished quality of life due to urinary 
symptoms [43]. 
11.3 Hot Flash Diary ( Appendix IV) 
The Hot Flash Diary is completed daily during each of the 6 weeks that patients are taking the 
study treatment. Like the Baseline Symptom Determination, the form has patients report the 
number and s everity of their daily hot flashes. Additionally, it has them report how many doses 
of the study drug they took on each day. Comp letion of the Hot Flash D iary is anticipated to 
take less than a minute per day . 
11.4 Symptom Experi ence Questionnaire ( Appendix V ) 
The Symptom Experience Questionnaire is col lected at the end each of the 7 weeks of the study 
period. This form collects patient reported toxicity and quality of life data using a 0 -10 scale, 
with one question that allows an unstructured response to report symptoms not captured in the 
questions provided. Estimated completion time for the Symptom Experience Questionnaire is 
10-15 minutes each week.  
Alliance A 222001  
35 
Version Date  09/14/22  Update #02  11.5 Hot Flash Related Daily Interference Scale (HRFDIS)  (Appendix VI) 
Hot Flash Related Daily Interference Scale (HFRDIS), a tool developed by [INVESTIGATOR_124]. Janet 
Carpenter. [33]  We recently asked [ADDRESS_903806] used the HFRDIS in men 
receiving androgen deprivation therapy [34-36]. These studies provide additional data 
supporting the reliability and validity of the 10 -item instrument in this population.  
The Hot Flash Related Daily Interference Scale is to  be completed by [CONTACT_669113] 
(Week 1) and at the conclusion of the study (Week 7). It will also be completed at the end of 
Weeks [ADDRESS_903807] two 
weeks.  This 10 -item questionnaire uses a 1 -10 sca le to ass ess the interference caused by [CONTACT_669114]’ personal lives. Each completion of the 
HFRDIS is expected to take [ADDRESS_903808] ( Appendix V II)  
All patients will receive weekly phone calls  from study staff,  to document compliance with 
study drug, encourage completion of requisite study questionnaires, and address any patient 
concerns or problems  and assess adverse events . The nurse weekly phone calls will continue 
during the optional cross over phase, to assess and collect adverse events during this time.  
12.0 END OF TREATMENT /INTERVENTION  
12.1 Duration of Protocol Treatment  
Protocol treatment is  to continue for 6 week s from the time of start of treatment . Please see the 
study calendar ( Section 5 .0) and the treatment section ( Section 7 .0) for treatment and follow up 
time periods.  
12.2 Criteria for Discontinuation of Protocol Treatment/I ntervention  
In the absence of treatment delays due to adverse event (s), treatment may continue until one of 
the following criteria applies:  
• Disease progression  (if applicable)  
• Intercurrent illness that prevents further administration of treatment  
• Unacceptable adverse event(s)  
• Patient decides to withdraw from the study  
• General or specific changes in the patient's condition render the patient unacceptable for 
further treatment in the judgment of the investigator  
• Patient non -compliance  
• Termination of the study by [CONTACT_3211]  
• The drug manufacturer can no longer provide the study agent  (if applicable)  
The reason(s) for protocol therapy discontinuation, the reason(s) for study removal, and the  
corresponding dates must be documented in the Case Report Form (CRF).  
Alliance A 222001  
36 
Version Date  09/14/22  Update #02  12.3 Follow -up  
12.3.1 Duration of Follow -up  
Protocol treatment is to continue for 6 weeks.  Please follow the data submission 
requirements outlined in the study calendar ( Section 5.0 ). There is no further clinical or 
survival follow up beyond the 6 -week study period. For patients who participate in the 
optional crossover phase, there will be a 6 -week follow up.  
12.3.2 Follow -up for Patients w ho Stop Study Treatment Early  
Protocol treatment is to continue for 6 weeks. Patients who do not complete 6 weeks of 
protocol treatment for any reason will still be expected to follow the data submission 
requirements outlined in the study calendar ( Section 5.0 ) and will thus be followed up until 
[ADDRESS_903809] -randomization.  
Follow up for patients who stop due to toxicity  
If the patient decides to discontinue the study medication because of unacceptable side 
effects , he is to call the study nurse.  The patient should be encouraged  to complete 
diaries/questionnaires to date and send them in. The patient can then be taken off study. 
The off -study date to be used is either (1) the day after the patient took some study 
medication OR (2) the day after the patient last recorded some research data on the patient 
questionnaire --whichever occurred last.  
12.4 Extraordinary Medical Circumstances  
If, at any time the constraints of this protocol are detrimental to the patient's he alth and/or the 
patient no longer wishes to continue protocol therapy, protocol therapy shall be discontinued. In 
this event:  
• Document the reason(s) for discontinuation of therapy on data forms.  
• Follow the patient for protocol endpoints as required by [CONTACT_618160].  
12.5 Managing ineligible patients and registered patients who never receive protocol 
intervention  
Definition of ineligible patient  
A study participant who is registered to the trial but does not meet all of the eligibility criteria 
is deem ed to be ineligible.  
Follow -up for ineligible patients who continue with protocol treatment  
Patients who are deemed ineligible after registering may continue protocol treatment, provided 
the treating physician, study chair, and executive officer agree there are no safety concerns if 
the patient continues protocol treatment. All scans, tests, and data submission are to continue as 
if the patient were eligible. Notification of the local IRB may be necessary per local IRB 
policies.  
Follow -up for  ineligible patients who discontinue protocol treatment  
For patients who are deemed ineligible after registering to the trial, who start treatment, but then 
discontinue study treatment, the same data submission requirements are to be followed as for 
those patie nts who are eligible and who discontinue study treatment.  
Follow -up for patients who are registered, but who never start study treatment  
For all study participants who are registered to the trial but who never receive study intervention 
(regardless of elig ibility), the follow -up re quirements are specified below:  
Alliance A 222001  
37 
Version Date  09/14/22  Update #[ADDRESS_903810]-randomization. All analyses will follow an intent -to-treat approach that includes all 
randomized patients who meet eligibility criteria . 
13.2 Study Design  
Patients will be randomly assigned to oxybutynin at 2.5 mL twice dai ly, oxybutynin at 5.0 mL 
twice daily, placebo at 2.5 mL twice daily,  or placebo at 5.0 ml twice daily in a 2:2:1:1 ratio 
according to the dynamic allocation scheme. Stratification factors will include daily hot flash 
frequency at baseline (4 to 9 hot flash es per day versus 10 or more hot flashes per day), hot flash 
duration at baseline (less than 9 months versus 9 or more months), and number of prior hot flash 
therapi[INVESTIGATOR_014] (0 versus 1 or more ). The study design includes two placebo arms to match the dose 
of th e two oxybutynin arms; however, patients randomized to the two placebo arms will be 
combined to form a single placebo arm for analysis. All analyses will follow an intent -to-treat 
approach that includes all randomized patients who meet eligibility criteria . 
13.3 Study Endpoints  
Important endpoints for this phase II trial relate to (1) efficacy of oxybutynin as measured by 
[CONTACT_669115] (primary) and hot flash frequency, (2) safety as measured by [CONTACT_669116] v5.0 -determined grade 3 or higher adv erse events, (3) tolerability as measured by 
[CONTACT_669117] -reported symptoms on the Symptom Experi ence Questionnaire ( Appendix V ), 
(4) feasibility regarding the conduct of this trial as measured by [CONTACT_669118] l and treatment 
adherence, and (5) patient -reported quality of life and hot flash interference as measured by [CONTACT_669119] (HFRDIS; Appendix VI). Treatment adherence rates 
will be calcul ated by [CONTACT_669120]. Hot flash scores and frequencies will be measured 
by [CONTACT_1962]’ hot flash diaries ( Appendix I V). Daily hot flash scores will be computed by 
[CONTACT_669121] a 24 -hour period by [CONTACT_669122] (grade 0: none, 1: mild, 2: moderate, 3: severe, and 4: very severe) and then summing 
all the values. Weekly hot flash scores will be computed by [CONTACT_669123] [ADDRESS_903811] 1 of the 7 days of each week  are available.  However, the  number of missing 
(daily) hot flash scores each week will be tabulated.  
13.4 Analysis Plan  
To assess efficacy , a mixed model will be estimated that includes baseline and weekly hot flash 
scores across the 6 -week treatment period. The mixed model will incl ude a fixed intercept; fixed 
effect for time, arm, and arm by [CONTACT_6491]; and residual covariance matrix based on the 
observed covariances. Alternative structures will be investigated for the residual covariance 
matrix, with final selection based on convergence of the mixed model and minimization of the 
Akaike information criterion. Stratification factors used in the randomization as well as baseline 
patient characteristics and prognostic factors may be included in the mixed model as covariates  
if imb alances across arms occur . For this mixed model, time will be treated as nominal (not 
continuous), such that the mixed model will not be making assumptions about the trajectory of 
Alliance A 222001  
38 
Version Date  09/14/22  Update #02  patients’ hot flash scores over time. Estimates from the mixed model will be  used to construct 
90% confidence intervals for mean differences in hot flash score reduction from baseline to [ADDRESS_903812] -randomization between the oxybutynin and placebo arms (i.e., Arm A versus Arms 
C and D combined; Arm B versus Arms C and D combined) . To control the Type I error rate, a 
fixed sequence procedure will be employed such that the following two tests will be sequenced 
rather than conducted simultaneously. Hot flash score reduction from baseline to 6 weeks  will 
be compared across pat ients as signed to oxybutynin at 5.0 m L twice daily (Arm B) and patients 
assigned to placebo (Arms C and D combined) using a contrast estimated via the mixed model. 
The contrast will involve a two -sided t-test with a nomin al significance level of α = .10. If and 
only if this test is significant, hot flash score  reduction from baseline to 6 weeks will be formally 
compared across patients assigned to oxybutynin at 2.5 mL  twice daily (Arm A) and patients 
assigned to placebo (Arms C and D combined) using a second contra st estimated via the mixed 
model. This contrast will also involve a two -sided t-test with a nomin al significance level of 
α = .10. The proposed sequencing is based on the assumption that the effect of oxybutynin will 
increase monotonic ally with respect to dose. If p ≤ .10 for both tests, we will conclude that both 
dosing schedules significantly improved hot flash scores  at 6 weeks relative to placebo. If 
p ≤ .[ADDRESS_903813] but p > .[ADDRESS_903814], we will conclude that the higher dosing 
schedule significantly improved hot  flash scores at 6  weeks relative to placebo but that the lower 
dosing schedule did not significantly improve hot flash scores  at 6 weeks rel ative to placebo. 
Finally, if p > .[ADDRESS_903815], we will conclude that neit her dosing schedule significantl y 
improved hot flash scores at 6  weeks relativ e to placebo. In practice, if p > .[ADDRESS_903816] a responder analysis at 6 weeks comparing the proportion of 
patients who experience a clinically significant improvement in hot flash scores since baseline 
across the oxybutynin and placebo arms using Fisher’s exact test, χ2 test, or logistic regression. 
Stratification factors used in the randomization as well as baseline patient characteristics and 
prognostic factors may be included in the logistic regression model as covariates  if imbalances 
across arms occur . A clinically significan t improvement will be defined as a 50% or greater 
reduction in hot flash scores since baseline based on preliminary evidence suggesting that 
patients consider a 50% or greater reduction in frequency of moderate to severe hot flashes to 
be a meaningful impr ovement.[41, 42] Patients who experience a 50% or greater reduction in 
hot flash scores since baseline will be deemed responders, while the remaining patients 
(including those with missing hot flash scores) will be deemed non -responders. As an 
exploratory analysis, we will investigate whether these efficacy results differ when using a 
single day rather than a full week to define patients’ baseline hot flash scores.  
Weekly hot flash frequencies  (as opposed to weekly hot flash scores) will be compared across 
the oxybutynin and placebo arms in a manner similar to above using a mixed model that 
accounts for the observed distribution of weekly hot flash frequencies. A fixed sequence 
procedure will be employed . For the responder analysis, patients who experience a  50% or 
greater reduction in hot flash frequency since baseline will be deemed responders, while the 
remaining patients (including those with missing hot flash frequencies) will be deemed non -
responders. Finally, consistency of the results will be assessed  across the various methods used 
to evaluate the efficacy of oxybutynin in this trial (i.e., hot flash scores versus hot flash 
frequencies, mean differences versus 50% or greater reduction since baseline, single day versus 
full week to define patients’ bas eline hot flash scores).  
To assess safety , the proportion of patients experiencing a grade [ADDRESS_903817] this proportion to be extremely low for all arms.  
To assess tolerability , mixed model s similar to the one described above will be estimated that 
include baseline and weekly patient -reported symptoms as measured by [CONTACT_669124] A 222001  
39 
Version Date  09/14/22  Update #02  Experience  Questionnaire ( Appendix V ) across the [ADDRESS_903818] 90% confidence intervals for mean differences in patient -reported 
symptoms between the oxybutynin and placebo arms (i.e., Arm A versus Arms C  and D 
combined; Arm B versus Arms C and D combined) at [ADDRESS_903819] with a nominal significance level 
of α = .10. 
To assess feasibility , the time required to accrue [ADDRESS_903820] 
with a phase III trial, an average accrual rate of 4 patients per month (starting 4 months after 
enrollment begins, to account for the time required for multiple institutions to activate the trial) 
would be desir ed. The treatment adherence rate (i.e., the number of patients who completed 
treatment per protocol divided by [CONTACT_669125]) will be 
summarized by [INVESTIGATOR_216].  
To assess patient -reported quality of life and hot flash interference , mixed model s similar 
to the one described above will be estimated that include patients’ scores on the HFRDIS 
(Appendix V I) across the [ADDRESS_903821] 90% confidence 
intervals for mean differences in patient -reported quality of life and hot flash interference 
between the oxybutynin and p lacebo arms (i.e., Arm A versus Arms C and D combined; Arm B 
versus Arms C and D combined) at [ADDRESS_903822] with a nominal significance level of α = .10. 
Attempts to min imize missing data  will be made through site training and data monitoring ( e.g., 
form delinquency notifications, queries; see Section 6.1.3).  The proportion of, and reported 
reasons for, missing data  will be presented by [CONTACT_669126]. Correlation ana lysis and 
logistic regression analysis will be used to examine whether baseline patient characteristics and 
prognostic factors predict missingness. The primary analysis will provide unbiased parameter 
estimates under a missing completely at random or missi ng at random mechanism. However, a 
sensitivity analysis will be conducted to assess the robustness of the results across various 
assumptions about the missing data.  
13.5 Sample Size and Power  
As this is a pi[INVESTIGATOR_4251], the sample size was determined based o n feasibility and logistical 
considerations rather than on power for hypothesis testing. We aim to enroll 26 evaluable 
patients per oxybutynin arm and 13 evaluable patients per placebo arm (i.e., 78 evaluable 
patients total). For the primary aim, 26 evalua ble patients per oxybutynin arm and 13 evaluable 
patients per placebo arm with 6 weekly hot flash scores provide 76% power to detect a mean 
difference in hot flash score reduction from baseline when comparing each oxybutynin arm (5.0 
mL twice daily or 2.5 mL twice daily  to the placebo arm ( both placebo arms combined ) based 
on a two -sided t-test estimated via a mixed model, nominal significance level of α = .10, 
intraclass correlation of .50, and population standardized mean difference of 0.50 (i.e., Cohen’s 
convent ion for a moderate effect size )[44]. In a similar study in women, Cohen’s d equaled 0.85 
when comparing the higher dose oxybutynin arm (2.5 mL twice daily escalated to 5.0 mL twice 
daily) to the placebo arm, and Cohen’s d equaled 0.54 when comparing the lower dose 
oxybutynin arm (2 .5 mL twice daily) to the placebo arm  [45]. An additional 9 patients will be 
accrued to account for a 10% loss in samp le size due to ineligibility, major treatment violation, 
or cancellation. Maximum projected accrual is, therefore, 87 patients.  
Alliance A 222001  
40 
Version Date  09/14/22  Update #[ADDRESS_903823] -recent 
previous male hot flash trial (conducted 15 years ago  to evaluate gabapentin ) and recent survey 
information . Therefore, the accrual period for this phase II trial is expected to be  13 months . 
The final analysis is predicted to begin  approximately  15 months after the trial begins ( i.e., as 
soon as the last patient has been observed for  6 weeks) . 
13.7 Data and Safety Monitoring  
The study chair(s) and the study statistician will review t he study at regular intervals to identify 
accrual  and adverse  event s. The Alliance Data Safety Monitoring Board (DSMB) is responsible 
for reviewing accrual and safety data for this trial at least twice a year, based on reports provided 
by [CONTACT_669127] (SD MC). 
Required submission of patient demographic data for this study will be submitted automatically 
via OPEN.   
Note: Serious adverse events must be submitted via CTEP -AERS per protocol guidelines.  
13.7.1 Adverse Event Stoppi[INVESTIGATOR_669071]. We note that the adverse event stoppi[INVESTIGATOR_669072] (1) the study re -opening to accrual or (2) at any time during t he conduct of the trial 
and in consideration of newly acquired information regarding the adverse event profile of 
the treatment(s) under investigation. The study team may choose to suspend accrual 
because of unexpected adverse event profiles that have not crossed the specified rule 
below.  
Accrual will be temporarily suspended to this study if at any time we observe adverse 
events considered at least possibly related to study treatment (i.e., an adverse event with 
attribute specified as “possible”, “probable”, or “definite”) that satisfy either of the 
following:  
• if [ADDRESS_903824] 10 treated patients experience a grade 3 or higher 
adverse event felt to be attributed to the study agent and the event rate is higher in 
the treatment arms  than the placebo arm.  
• if after the first [ADDRESS_903825] been treated, 10% of all patients experience a 
grade 3 or higher adverse event felt to be attributed to the study agent and the event 
rate is higher in the treatment arms than the placebo arm.  
We n ote that we will review grade 4 and 5 adverse events deemed “unrelated” or “unlikely 
to be related,” to verify their attribution and to monitor the emergence of a previously 
unrecognized treatment -related adverse event.  
13.[ADDRESS_903826] ate cancer is greater in African  American men. Given 
this, an Alliance Health Disparities Committee member was added as a study co -chair to 
Alliance A 222001  
41 
Version Date  09/14/22  Update #02  facilitate  appropriate accrual of minority patients. Efforts will be made to accrue  a substantial 
number of African  American men to this trial.  
Based on prior Alliance studies involving similar disease sites, expected sizes of racial and 
ethnic subsets for patients registered to this study are shown in the following table:  
13.9 Inclusion of Minorities  
PLANNED ENROLLMENT  REPORT  
Racial Categories  Ethnic Categories  
Total  Not Hispanic or Latino  Hispanic or Latino  
Female  Male  Female  Male  
American Indian/ 
Alaska Native  0 1 0 0 1 
Asian  0 1 0 0 1 
Native Hawaiian or 
Other Pacific 
Islander  0 1 0 0 1 
Black or African 
American  0 9 0 0 9 
White  0 70 0 4 74 
More Than One 
Race  0 1 0 0 1 
Total  0 83 0 4 87 
Ethnic Categories:   
• Hispanic or Latino – a person of Cuban, Mexican, Puerto Rican, South or Central 
American, or other Spanish culture or origin, regardless of race. The term “Spanish 
origin” can also be used in addition to “Hispanic or Latino.”  
• Not Hispanic or Latino  
Racial Categories : 
• American Indian or Alaskan Native – a person having origins in any of the original 
peoples of North, Central, or S outh America, and who maintains tribal affiliations or 
community attachment.  
• Asian – a person having origins in any of the original peoples of the Far East, Southeast 
Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, 
Korea, Malaysia, Pakistan, the Philippi[INVESTIGATOR_31922], Thailand, and Vietnam. (Note: 
Individuals from the Philippi[INVESTIGATOR_669073].)  
• Black or African American – a person having origins in  any of the black racial groups 
of Africa.  
• Native Hawaiian or other Pacific Islander – a person having origins in any of the original 
peoples of Hawaii, Guam, Samoa, or other Pacific Islands.  
• White – a person having origins in any of the original peoples of Europe, the Middle 
East, or North Africa.  
  
Alliance A 222001  
42 
Version Date  09/14/22  Update #[ADDRESS_903827] be able to rebottle liquid formulation  
of drug and placebo  into patient specific supplies. In order for the Alliance to monitor starter supply 
distribution, institutions are asked to document their commitment to the requirements of the study  as 
follows:   
• In order for a site to be considered for the study, a “Site Participation Form” must be completed.  
The form can be requested from and once completed returned to    
• Upon approval, the site will be added to the list of limited access institutions with the next update 
to this protocol.  
Sites will receive extra per patie nt reimbursement for the effort invol ved with rebottling liquid 
formulations of the drug.  
15.[ADDRESS_903828] (DSMB)  as outlined in Section 13. 7.  

Alliance A 222001  
43 
Version Date  09/14/22  Update #02  16.0 REFERENCES  
1. Nguyen, P.L., et al., Adverse effects of androgen deprivation therapy and strategies to mitigate 
them.  Eur Urol, 2015. 67(5): p. [ADDRESS_903829] carcinoma: A nationwide case series of 35 patients in The Netherlands.  Head Neck, 2018. 
40(3): p. [ADDRESS_903830] 
Cancer, 2015. 15(4): p. 24 5-50. 
4. Thompson, C.A., T.D. Shanafelt, and C.L. Loprinzi, Andropause: symptom management for 
prostate cancer patients treated with hormonal ablation.  Oncologist, 2003. 8(5): p. 474 -87. 
5. Jones, J.M., M. Kohli, and C.L. Loprinzi, Androgen deprivation therapy -associated vasomotor 
symptoms.  Asian J Androl, 2012. 14(2): p. 193 -7. 
6. Clark, J.A., et al., Dimensions of quality of life expressed by [CONTACT_669128].  Soc Sci Med, 1997. 45(8): p. 1299 -309. 
7. Challapalli, A., et al., Evaluating the prevalence and predictive factors of vasomotor and 
psychological symptoms in prostate cancer patients receiving hormonal therapy: Results from a 
single institution experience.  Clin Transl Radiat Oncol, 2018. 10: p. 29 -35. 
8. Gonzalez, B.D., et al., Sleep disturbance in men receiving androgen deprivation therapy for 
prostate cancer: The role of hot flashes and nocturia.  Cancer, 2018. 124(3): p. 499 -506. 
9. Hunter, M.S. and E. Stefa nopoulou, Vasomotor symptoms in prostate cancer survivors 
undergoing androgen deprivation therapy.  Climacteric, 2016. 19(1): p. [ADDRESS_903831], J., S. Hervouet, and H. Ivers, Prostate cancer treatments and their side effects are 
associated with increased  insomnia.  Psychooncology, 2013. 22(6): p. 1381 -8. 
11. Sharpley, C.F., V. Birsika, and J.W. Denham, Factors associated with feelings of loss of 
masculinity in men with prostate cancer in the RADAR trial.  Psychooncology, 2014. 23(5): p. 
524-30. 
12. Loprinzi , C.L., et al., Megestrol acetate for the prevention of hot flashes.  N Engl J Med, 1994. 
331(6): p. 347 -52. 
13. Irani, J., et al., Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for 
the treatment of vasomotor hot flushes in m en taking gonadotropin -releasing hormone analogues 
for prostate cancer: a double -blind, randomised trial.  Lancet Oncol, 2010. 11(2): p. 147 -54. 
14. Bonkhoff, H., et al., Progesterone receptor expression in human prostate cancer: correlation 
with tumor prog ression.  Prostate, 2001. 48(4): p. 285 -91. 
15. Sartor, O. and J.A. Eastham, Progressive prostate cancer associated with use of megestrol 
acetate administered for control of hot flashes.  South Med J, 1999. 92(4): p. 415 -6. 
16. Geller, J., J. Albert, and S.S. Yen, Treatment of advanced cancer of prostate with megestrol 
acetate.  Urology, 1978. 12(5): p. 537 -41. 
17. Burch, P.A. and C.L. Loprinzi, Prostate -specific antigen decline after withdrawal of low -dose 
megestrol acetate.  Journal of clinical oncology, 1999. 17(3): p. 1086a -1086a.  
18. Loprinzi, C.L., et al., A phase III randomized, double -blind, placebo -controlled trial of 
gabapentin in the management of hot flashes in men (N00CB).  Ann Oncol, 2009. 20(3): p. [ADDRESS_903832] of venlafaxine and soy protein on hot 
flashes and quality of life in men with prostate cancer.  J Clin Oncol, 2013. 31(32): p. 4092 -8. 
20. Joffe, H., et al., Low-dose estradiol and the serotonin -norepi[INVESTIGATOR_669074]: a randomized clinical trial.  JAMA Intern Med, 2014. 
174(7): p. 1058 -66. 
21. Evans, M.L., et al., Management of postmenopausal hot flushes with venlafaxine hydrochloride: a 
randomized, controlled trial.  Obstet Gynecol, 2005. 105(1): p. 161 -6. 
Alliance A 222001  
44 
Version Date  09/14/22  Update #02  22. Artzi, O., et al., Topi[INVESTIGATOR_669075] 10% Gel for the Treatment of Primary Focal Hyperhidrosis: 
A Randomized Double -blind Placebo -controlled Split Area Study.  Acta Derm Venereol, 2017. 
97(9): p. 1120 -1124.  
23. Wolosker, N., et al., Oxybutynin treatment for hyperhidrosis: a comparative analysis between 
genders.  Einstein (Sao Paulo), 2012. 10(4): p. 405 -8. 
24. Campanati, A., et al., Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of 
the A rt. Skin Appendage Disord, 2015. 1(1): p. 6 -13. 
25. Medicine, U.S.N.L.o. MedlinePlus -Oxybutynin Drug Information .  01/04/2019]; Available from: 
https://medlineplus.gov/druginfo/meds/a682141 .html . 
26. Sexton, T., et al., Oxybutynin for refractory hot flashes in cancer patients.  Menopause, 2007. 
14(3 Pt 1): p. 505 -9. 
27. Simon, J.A., et al., Extended -release oxybutynin therapy for vasomotor symptoms in women: a 
randomized clinical trial.  Menopause, 2016. 23(11): p. 1214 -1221.  
28. Leon -Ferre, R.A., et al., A randomized, doubleblind, placebo -controlled trial of oxybutynin (Oxy) 
for hot flashes (HF): ACCRU study SC -1603.  Cancer Research, 2019. 79(4). 
29. Smith, T.J., C.L. Loprinzi, and C. De ville, Oxybutynin for Hot Flashes Due to Androgen 
Deprivation in Men.  N Engl J Med, 2018. 378(18): p. 1745 -1746.  
30. Sloan, J.A., et al., Methodologic lessons learned from hot flash studies.  J Clin Oncol, 2001. 
19(23): p. 4280 -90. 
31. Quella, S., C.L. Lopr inzi, and A.M. Dose, A qualitative approach to defining "hot flashes" in 
men.  Urol Nurs, 1994. 14(4): p. [ADDRESS_903833] -orchiectomy hot flashes.  J 
Urol, 1994. 151(3): p. 634 -6. 
33. Carpenter, J.S., The Hot Flash Related Daily Interference Scale: a tool for assessing the impact 
of hot flashes on quality of life following breast cancer.  J Pain Symptom Manage, 2001. 22(6): p. 
979-89. 
34. Gonzalez, B.D., et al., Course and Moderators of Hot Flash I nterference during Androgen 
Deprivation Therapy for Prostate Cancer: A Matched Comparison.  J Urol, 2015. 194(3): p. 690 -
5. 
35. Beer, T.M., et al., Acupuncture for hot flashes in patients with prostate cancer.  Urology, 2010. 
76(5): p. 1182 -8. 
36. Rich, T., et al., Intermittent 96 -Hour Auricular Electroacupuncture for Hot Flashes in Patients 
with Prostate Cancer: A Pi[INVESTIGATOR_16116].  Med Acupunct, 2017. 29(5): p. 313 -321. 
37. Kay, G., et al., Differential effects of the antimuscarinic agents darifenacin and oxybuty nin ER on 
memory in older subjects.  Eur Urol, 2006. 50(2): p. [ADDRESS_903834] of solifenacin and oxybutynin in elderly people with mild cogniti ve 
impairment: the SENIOR study.  Eur Urol, 2013. 64(1): p. 74 -81. 
39. Katz, I.R., et al., Identification of medications that cause cognitive impairment in older people: 
the case of oxybutynin chloride.  J Am Geriatr Soc, 1998. 46(1): p. [ADDRESS_903835], safety, and 
tolerability of oral extended -release oxybutynin in cognitively impaired nursing home residents 
with urge urinary incontinence.  J Am Geriatr Soc, 2008. 56(5): p. 862 -70. 
41. Pocock, S.J. and R. Simon, Sequential treatment assignment with balancing for prognostic 
factors in the controlled clinical trial.  Biometrics, 1975: p. 103 -115. 
42. Barry, M. and F. Fowler Jr, O’Leary MP et al. The American Urological Association symp tom 
index for benign prostatic hyperplasia. The Measurement Committee of the American Urological 
Association.  J Urol, 1992. 148(5): p. [ADDRESS_903836] SYMPTOMS IN 
COMMUNITY DWELLING OLDER MEN.  The Journal of Urology, 2010. 183(4S): p. e195 -e195.  
Alliance A 222001  
45 
Version Date  09/14/22  Update #02  44. Cohen, J., Statistical Power Analysis for the Behavioral Sciences (2nd edn), [ADDRESS_903837] Cancer: A Randomized, Double -Blind Clinical Trial (ACCRU SC -1603).  JNCI Cancer 
Spectrum, 2020. 4(1): p. pkz088.  
 
 
 
Alliance A 222001  
46 
Version Date  09/14/22  Update #[ADDRESS_903838] been given by [CONTACT_669129]. One  or more of these 
descriptions may help to categorize your hot flash as mild, moderate, severe, or very 
severe.  
 
MILD  
Duration: Lasting less than 3 minutes  
Physical symptoms: Very light perspi[INVESTIGATOR_1516], generalized warmth or a flushed 
sensation  
Emotional symptoms: None or rare  
Action needed: Usually no action taken  
 
MODERATE  
 Duration: Lasting up to 5 minutes  
Physical symptoms: Light -to-moderate perspi[INVESTIGATOR_1516], m oderate warmth and/or 
perspi[INVESTIGATOR_669076]: Mild anxiety, some irritability, loss of concentration  
Action needed: Needed to use a fan, needed to loosen clothing, needed to remove clothing, 
needed to remove bedding  
 
SEVERE  
Duration: Lasting up to 10  minutes  
Physical symptoms: Described as feeling “hotter” or “very hot,” heavy perspi[INVESTIGATOR_1516], 
dizziness, nausea, shortness of breath, weakness, extreme discomfort  
Emotional symptoms: Moderate anxiety, moderate irritability  
Action needed: Needed to loosen clothing, needed to change clothing, needed to change bedding  
 
VERY SEVERE  
Duration: Lasting up to 30 minutes  
Physical symptoms: Described as feeling “very hot,” drenching perspi[INVESTIGATOR_1516], dizziness, 
nausea, shortness of breath, weakn ess, chest discomfort, extreme discomfort  
Emotional symptoms: Severe anxiety, severe irritability, restlessness, totally out of control  
Action needed: Needed to change clothing, needed to towel off, needed to change 
bedding, used wet towels, took a bath or  shower, needed a rest  
Alliance A 222001  
47 
Version Date  09/14/22  Update #02  APPENDIX II BASELINE SYMPTOM DOCUMENTATION   
___________________________________________________________________________________  
 
Directions:  
• The baseline symptom determination is divided into 7 rows, one for each day of the week.  
• Enter the day and the date your week started.  
• Start in the row for Day 1.  
• Write in the number of mild, moderate, severe and very severe hot flashes experienced in the 
boxes.  
• Repeat for each day of the week.  
• See page 2 of this booklet for the definition s of each type of hot f lashes.  
 
Day week started: _____________________ Date week started: __ __ / __ __ / __ __ __ __  
        m m     d d       y   y    y   y  
 
 
Day Number of mild 
hot flashes  Number of 
moderate hot 
flashes  Number of 
severe hot 
flashes  Number of 
very severe 
hot flashes  
Day 1      
Day 2      
Day 3      
Day 4      
Day 5      
Day 6      
Day 7      
 
*A day should be considered a 24 -hour period (i.e. 7 a.m. to 7 a.m. or midnight to midnight) . 
  
Alliance A 222001  
48 
Version Date  09/14/22  Update #02  APPENDIX III INTERNATIONAL PROSTATE SYMPTOM SCORE (IPSS)   
(To be completed at screening and at the end of each week of treatment )  
INTERNATIONAL -PROSTATE SYMPTOM SCORE  
Question  Not at all  Less than  
[ADDRESS_903839] you had a 
sensation of not emptying 
your bladder completely 
after you finished 
urinating?  [ADDRESS_903840] you had to 
urinate again less than two 
hours after you finished 
urinating?  [ADDRESS_903841] you found you 
stopped and started again 
several times when you 
urinated?  [ADDRESS_903842] you found it 
difficult to postpone 
urination?  [ADDRESS_903843] you had a weak 
urinary stream?  [ADDRESS_903844] you had to push 
or strain to begin urination?  [ADDRESS_903845] 
typi[INVESTIGATOR_669077]?  0 1 2 3 4 5 
I-PSS - [LOCATION_002]/English  
ID 5070 / I-PSS1a_AU1.0_eng -USori.doc   
 
  
Alliance A 222001  
49 
Version Date  09/14/22  Update #02  INTERNATIONAL -PROSTATE SYMPTOM SCORE (cont'd)  
QUALITY OF LIFE DUE TO URINARY SYMPTOMS  
Question  Delighted  Pleased  Mostly  
satisfied  Mixed about  
equally  
satisfied and  
dissatisfied  Mostly  
dissatisfied  Unhappy  Terrible  
1. If you were to 
spend the rest of 
your life with your 
urinary condition just 
the way it is now, 
how would you feel 
about that?  0 1 2 3 4 5 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I-PSS - [LOCATION_002]/English  
ID 5070 / I-PSS1a_AU1.0_eng -USori.doc  
 
Alliance A 222001  
50 
Version Date  09/14/22  Update #02  APPENDIX IV HOT FLASH DIARY  (SAMPLE INCLUDED ON THE NEXT PAGE )  
_____________________________________________________________________________________  
 
Directions:  
 
The hot flash diary is divided into 7 rows, one for each day * of the week.  
Enter the day and the date your week started.  
Start in the row for Day 1.  
Write in the number of mild, moderate, severe and very severe hot flashes experienced in the 
boxes.  
Repeat for each day of the week.  
See page 2 of this booklet for t he definitions of each type of hot f lashes.  
 
Day week started: _____________________ Dat e week started: __ __ / __ __ / __ __ __ __  
        m m     d d       y   y    y   y  
 
 
Day Number of mild 
hot flashes  Number of 
moderate hot 
flashes  Number of 
severe hot 
flashes  Number of 
very severe 
hot flashes  How many 
doses of study 
medication 
did you take?  
(circle one)  
Day 1      0   1    2  
Day 2      0   1    2  
Day 3      0   1    2  
Day 4      0   1    2  
Day 5      0   1    2  
Day 6      0   1    2  
Day 7      0   1    2  
 
*A day should be considered a 24 -hour period (i.e. 7 a.m. to 7 a.m. or midnight to midnight) . 
 
Alliance A 222001  
51 
Version Date  09/14/22  Update #02   
  

Alliance A 222001  
52 
Version Date  09/14/22  Update #02  APPENDIX V SYMPTOM EXPERIENCE QUESTIONNAIRE  
Completed at baseline and weekly for six weeks  
 
Date  completed:    
 
INSTRUCTIONS: Please complete at the end of each study week by [CONTACT_669130].  
 
1. Over the past week, have you experienced stomach pain or  cramps?  
 
[ADDRESS_903846] you experienced diarrhea (loose  stools)?  
 
[ADDRESS_903847] you experienced  constipation?  
 
[ADDRESS_903848] you experienced  nausea?  
 
[ADDRESS_903849] you experienced any  vomiting?  
 
[ADDRESS_903850] you experienced dry  mouth?  
 
0 1 2 3 4 5 6 7 8 9 10 
Not 
at all           As bad as 
it can be  
  
Alliance A 222001  
53 
Version Date  09/14/22  Update #[ADDRESS_903851] you experienced  dizziness?  
 
[ADDRESS_903852] you experienced decrease in  appetite?  
 
[ADDRESS_903853] you experienced  headaches?  
 
[ADDRESS_903854] you experienced  fatigue?  
 
[ADDRESS_903855] you experienced excessive  somnolence  (sleepi[INVESTIGATOR_008]) ? 
 
[ADDRESS_903856] you experienced blurry  vision?  
 
[ADDRESS_903857] you experienced dry  eyes?  
 
0 1 2 3 4 5 6 7 8 9 10 
Not 
at all           As bad as 
it can be  
 
  
Alliance A 222001  
54 
Version Date  09/14/22  Update #[ADDRESS_903858] you experienced epi[INVESTIGATOR_669078]?  
 
[ADDRESS_903859] you had a skin  rash?  
 
[ADDRESS_903860] week, did you experience any muscle/joint aches or  pains?  
 
[ADDRESS_903861] week, did you experience trouble  sleepi[INVESTIGATOR_007]?  
 
[ADDRESS_903862] you had trouble  concentrating?  
 
[ADDRESS_903863] you experienced any difficulties with your memory?  
 
[ADDRESS_903864] you experienced difficulties urinating (difficulties emptying your  bladder)?  
 
[ADDRESS_903865] you experienced any trouble with urine incontinence (leaking)?  
 
0 1 2 3 4 5 6 7 8 9 10 
Not 
at all           As bad as 
it can be  
 
  
Alliance A 222001  
55 
Version Date  09/14/22  Update #[ADDRESS_903866] week, how distressing was your experience with hot  flashes?  
 
[ADDRESS_903867] week that were not mentioned above?  
 
No  Yes   
If so, please  describe  
The following question will ONLY be asked at baseline:  
 
23a. How much do you think the study medication will be able to help hot  flashes?  
 
0 1 2 3 4 5 6 7 8 9 10 
Probably 
won’t  
work           Will work 
extremely  
well 
 
 
The following question will NOT be asked at baseline:  
 
23b. Over the past week, how satisfied are you with the control of your hot flashes?  
 
0 1 2 3 4 5 6 7 8 9 10 
Extremely 
Satisfied           Extremely 
Dissatisfied  
 
 
23c  Given your experience with the study medication on this trial would you want to continue 
it after the trial is over if given the choice?  
 
No  Yes   
 
  
Alliance A 222001  
56 
Version Date  09/14/22  Update #02  APPENDIX VI HOT FLASH RELATED DAILY INTERFERENCE SCALE (HFRDIS)  
Completed on Day  7, at the end of Weeks 3, 5, and 7 (i.e., Days 21, 35, and [ADDRESS_903868] of your life.  
  Did not  Completely  
 interfere  interfered  
1. Work  (work outside the 
home and housework)  
 
  0 1 2 3 4 5 6 7 8 9 10 
 
 
2. Social activities  (time 
spent with family, friends, 
etc) 
  0 1 2 3 4 5 6 7 8 9 10 
 
 
3. Leisure activities  (time 
spent relaxing, doing 
hobbies, etc.)  
  0 1 2 3 4 5 6 7 8 9 10 
 
 
4. Sleep  
 
  0 1 2 3 4 5 6 7 8 9 10 
 
5. Mood  
 
  0 1 2 3 4 5 6 7 8 9 10 
 
6. Concentration  
 
  0 1 2 3 4 5 6 7 8 9 10 
 
7.   Relations with others  
 
  0 1 2 3 4 5 6 7 8 9 10 
 
8.   Sexuality  
 
  0 1 2 3 4 5 6 7 8 9 10 
 
9.   Enjoyment of life  
 
  0 1 2 3 4 5 6 7 8 9 10 
 
10. Overall quality of life  
 
  0 1 2 3 4 5 6 7 8 9 10 
 
 
HFRDIS © 2001 Janet S. Carpenter  
 
  
Alliance A 222001  
57 
Version Date  09/14/22  Update #02  APPENDIX VII NURSE /CRP  PHONE CONTACT [CONTACT_669131].__________________  
Best Dates/Times to  call_____________  
 
FOLLOW UP:  
 
1. Please make an appointment to call the patient at home the end of each study 
week. The purpose of this contact [CONTACT_669132], 
document compliance, encourage completion of the booklet, and address  
problems.  
 
• It is important to reinforce daily completion of diary as well as 
weekly side effects on symptom experience questionnaire. 
Regarding potential side effects, please ask about dry mouth,  
nausea, vomiting, dizziness, blurred vision, dry eyes, urinary 
retention, and urinary incontinence. If there are any significant 
toxicities, then refer to protocol   Section 8.2 for potential dose 
modifications. I n addition, determine whether there are any 
reportable adverse events ( Section 9.0). 
 
2. Items to document on the Nurse/CRP Evaluation form in the forms packet include, but 
are not limited to the  following:  
• Date of phone  call 
• Study  week  
• Side effects:  
➢ Type of side effect, severity and attribution, if  applicable  
• Any changes in medications or other treatments (i.e. behavioral, diet,  etc.) 
• Has the participant taken the proper amount of study 
medication each day? (Choose  one: Always   , 
Usually   , Rarely   , or Never   ) 
• Questions/Comments  
 
3. Reinforce compliance with study medication.  
 
4. Reinforce completion of questionnaires and request return of them at end of weeks 1 and  4. 
 
Note – If patient dec ides to stop study before week 7 , ask them to fill out the questionnaires up to 
that point at the end of the booklet and return in the envelope provided.  
  
Alliance A 222001  
58 
Version Date  09/14/22  Update #02  APPENDIX  VIII: PATIENT MEDICATION DIARY – OXYBUTYNIN /PLACEBO   
(For patient and site convenience only)  
Today’s da te ______________________________   
Patient Name ___________________ (initials acceptable)  Patient Study ID  ____________  
 
 INSTRUCTIONS FOR THE PATIENT:  
1. Complete this form while you take oxybutynin/placebo .  This form is a  7 day diary .  You may 
need to complete more than one form between clinic visits, for each week of treatment.  
2. You will take your dose of oxybutynin/placebo twice daily.   You will be given an oral syringe to 
measure and take your medication, which you will clean and reuse during the c ourse of the 
study.  
3 Take the oxybutynin/placebo at least one hour before a meal or at least two hours afterwards.  
4. Record the date, the dose you took, and when you took it. Record doses as soon as you take 
them; do not batch entries together at a later  time.  
5. If a dose is missed, do not make up that dose; resume dosing with the next scheduled dose.  
6. Use extreme caution when oxybutynin is administered with any other anticholinergic agents as 
increased side effects can occur (i.e dry mouth, constipati on, somnolence).  
2. Report any unusual rapid heart rates to your doctor . 
3. Report skin changes  like rash  to your doctor.  
4. You may have decreased sweating abilities. Use caution if out in the heat and to avoid becoming 
overheated.  
5. Gastrointestinal effects can be seen including constipation, decreased GI motility, nausea, 
vomiting, and dry mouth.  
6. If you have trouble urinating, report this to  your doctor . 
7. Use caution when operating a vehicle or other activities that require close attention.  
8. Effects on the eye can include amblyopia (lazy eye), cycloplegia (paralysis of ciliary muscle -
leading to inability to focus on close objects), decreased tears and mydriasi s (abnormal pupil 
dilation).  Report any of these to your doctor.  
9. If you have any comments or notice any side effects, please record them in the comments 
column. If you make a mistake while you write, please cross it out with one line, put your initial s 
next to it, and then write the corrected information next to your initials.   
10. Please return this form to your doctor  or study staff . You may need to return more than one form 
per clinic visit.  
  
Alliance A 222001  
59 
Version Date  09/14/22  Update #02  WEEK: __________  
 
  Day Date  Time of daily dose  Dose#1  Dose#2  Comments  
1      
2      
3      
4      
5      
6      
7      
Patient’s Signature  
 
 [CONTACT_669137] A 222001  
60 
Version Date  09/14/22  Update #02  APPENDIX IX PATIENT INFORMATION SHEETS   
PATIENT INFORMATION SHEET  
BASELINE  
 
Patient Completed Quality of Life Booklet ( Baseline /Week 1 ) 
________________________________________________________________________  
 
You have been given a booklet to complete for this study.  The booklet contains some questions 
about your ‘quality of life’ as a patient receiving treatment for hot flashes .  Your an swers will help 
us to better understand how the treatment you are receiving is affecting the way you feel.  
 
Do not take any study medication this week.  
 
1. This booklet is to be completed before you start study treatment . 
 
2. The booklet contains 3  set of questions:  
a. Baseline Symptom Documentation  (Days 1 -7). This should be completed daily.  
On page 2 of this booklet, you will find examples of the different hot flash intensities: 
mild, moderate, severe, and very severe hot flash. This is to help you to decide the 
intensity of your hot flash, but it is not an absolute rule. Your hot flashes may differ in 
some ways or may fall just between two descriptions. Try to get as close as you can, but 
do not worry if your hot flashes do not match exactly wha t is given.  
b. Symptom Experience Questionnaire  (Day 7)  
c. Hot Flash Related Daily Interference Scale ( HFRDIS)  (Day 7)  
 
3. Directions on how to complete this set of questions are written on the top of the page.  
 
4. Please return your booklet , in the envelope provided or in person when you are finished . 
 
 
Thank you for taking the time to help  us. 
  
Alliance A 222001  
61 
Version Date  09/14/22  Update #02   
PATIENT INFORMATION SHEET  
TREATMENT  
Patient Completed Quality of Life Booklet (Weeks 2 -7) 
________________________________________________________________________  
 
You have been given a booklet to complete for this study.  The booklet contains some questions 
about your ‘quality of life’ as a patient receiving treatment for hot flashes .  Your answers will help 
us to better understand how the treatment you are receiving is affecting the way you feel.  
 
 
1. This booklet is to be completed on days 8-49, while you are receiving treatment. It is divided up 
into 6 weeks.  
 
2. The booklet contains 4  set of questions:  
a. Hot Flash Diary (every day during treatment) : This should be completed daily.  
On page 2 of this booklet, you will find examples of the different hot flash intensities: 
mild, moderate, severe, and very severe hot flash. This is to help you to decide the 
intensity of your hot flash, but it is not an absolute rule. Your hot flashes may differ in 
some ways or may fall just between two descriptions. Try to get as close as you can, but 
do not worry if your hot flashes do not match exactly what is  given.  
b. Symptom Experience Questionnaire (at the end of every week)  
c. International Prostate Symptom Score  tool (at the end of every week)  
d. Hot Flash Related Daily Interference Scale (HFRDIS)  (at the end of Weeks 2 and 4 of 
treatment, and at the end of treat ment)   
 
3. Directions on how to complete this set of questions are written on the top of the page.  
 
4. You may call a member of the study team to answer any questions you might have.  You will be 
given a name [CONTACT_41319].  You can call anytime with any concerns or questions. A 
nurse/research coordin ator will also call you at the end of every week  and they can answer 
questions you might have.  
 
5. It is very important that you return the booklet to us, whether you finish the study or not.  
 
6. When the booklet is complete, return it in the provided envelope.  
 
 
Thank you for taking the time to help  us.  
  
Alliance A 222001  
62 
Version Date  09/14/22  Update #[ADDRESS_903869] to all of your 
healthcare providers and keep 
it with you in case you go to 
the emergency room.  
Patient Name:        
[CONTACT_25562]:        
Study Doctor:       
Study [CONTACT_25567] #:       
NCI Trial #:  04600336  
Study Drug(S):  oxybutynin or Placebo  
 
 
 
 
For more information : 1-800-4-CANCER  
 
  

Alliance A 222001  
63 
Version Date  09/14/22  Update #[ADDRESS_903870] to further tailor the text to their situation.  
This small gesture is a part of a broader program being undertaken by [CONTACT_669133] i mprove accrual and follow -through.  
We appreciate your help in this effort.  
____________________________________________________________________  
Sample Template  
[PARTICIPANT NAME ] [DATE ] [PARTICIPANT ADDRESS ]  
Dear [ PARTICIPANT SALUTATION ],  
Thank you fo r agreeing to take part in this important research study. With the help of people like 
you who participate in clinical trials, we will achieve our goal of effectively treating and ultimately 
curing cancer.  
There are many reasons why individuals choose to participate in a clinical trial. Sometimes it is 
because they want access to a specific medication or because they want to do whatever they 
can to help someone else with cancer.  Whatever your reason for participating, you are making 
a contribution towards  finding better treatments and ultimately eliminating this disease for future 
patients.  
You will receive high quality care while participating in this clinical trial. My research staff and I 
will maintain very close contact [CONTACT_56150]. This will allow me to provide you with the best care 
while learning as much as possible to help you and other participants.  
On behalf of [INSTITUTION ] and the Alliance for Clinical Trials in Oncology, we thank you again 
for your participation in this clinical trial and look forward to partnering with you.  
Sincerely, [ PHYSICIAN NAME ]  
 
